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 Cancer is the second leading cause of death in the US and worldwide, accounting for 
16% of deaths worldwide in 2015.  Of more than 100 types of cancers affecting humans, breast 
cancer is the most common cancer among women and is the second leading cause of death in 
women.  Triple negative breast cancer (TNBC) is a subtype of breast carcinomas defined by the 
lack of the expression of estrogen receptor (ER), progesterone receptor (PR) and human 
epidermal growth factor receptor (HER2 /neu).  The prognosis and survival of TNBC patients 
remains the poor due to the lack of effective targeted therapy.   
Nanotechnology-based drug delivery systems, such as liposomes, are widely investigated 
to enhance anticancer efficacy by concentrating the drug molecules in the tissues of interest and 
by altering the pharmacokinetic profile.  Taking advantage of the pH gradient in the tumor 
microenvironment, pH-triggered release is a promising strategy to enhance the anticancer 
efficacy of drug delivery systems against TNBC.  Previously, a strategy in our lab has been 
developed to render saturated and pegylated liposomes pH-sensitive: protonation-induced 
conformational switch of lipid tails, using trans-2-aminocyclohexanol lipids (TACH, flipids) as a 
molecular trigger.  Based on previous work in our lab, pH-sensitive liposomes (fliposomes) 
composed of C-16 flipids with amine group of morpholine (MOR) and azetidine (AZE) 
demonstrated optimized triggered release in response to the tumor’s low pH microenvironment.    
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In this study, different preparation methods were developed and optimized to produce 
viable fliposomes with high doxorubicin (DOX) encapsulation efficiency.  In vitro release assays 
were established and validated to accurately reflect pH-triggered release of fliposomes.  The 
physicochemical properties of DOX-loaded fliposomes were characterized and their pH-
dependent release were investigated.  Factors influencing the desirable attributes of liposomes, 
such as size, pH-sensitivity, stability and drug-loading capacity were explored.  Based on these 
characterizations, central composite design (CCD) was utilized to optimize the formulation of 
fliposome with two critical factors, flipids and cholesterol. 
Cell viability assays on traditional monolayer and innovative three-dimensional 
multicellular spheroids (3D MCS) of TNBC cell lines were conducted to evaluate the anticancer 
efficacy of the resultant fliposomes in vitro.  The constructed 3D MCS carried heterogeneously 
distributed live and apoptotic cells, as well as acidity inside the 3D MCS based on confocal 
microscopic imaging studies.  The distribution and penetration of DOX-loaded fliposomes into 
3D MCS was imaged by confocal microscopy in comparison to DOX-loaded non pH-sensitive 
liposomes and free DOX.  As a result, fliposome manifested superior anticancer activity against 
TNBC 3D MCS by efficient penetration into 3D MCS, followed by tuning up the release rate of 
the anticancer agent DOX.   
A TNBC orthotopic xenograft model was established by transplanting TNBC into the 
murine mammalian fat pad, which maintains the organ-specific tumor microenvironment of the 
original organ.  A pilot pharmacokinetic study was conducted in order to correlate the pH 
response and stability properties with the in vivo stability of the optimized AZE-C16 fliposome.  
The antitumor efficacy was comparable between free DOX and DOX-loaded stealth liposome 
with tumor volumes of ~ 80-90% of the control treatment 32 days post first dose.  In contrast, the 
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DOX-loaded fliposome, especially MOR-C16 fliposome, exhibited a significantly higher 
antitumor efficacy and delayed progression compared to free DOX and stealth liposome 
treatments. 
Taken together, DOX-loaded fliposomes were successfully prepared and optimized for in 
vivo application.  They were able to achieve superior activity against TNBC in vitro and in vivo, 
facilitated by enhanced release of the anticancer drug DOX after penetration inside TNBC tumor. 
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Chapter 1: Introduction 
 
1.1 Statement of the Problem 
1.1.1 Triple negative breast cancer (TNBC).  Cancer is a large group of related 
diseases that involves rapid and abnormal proliferation of cells with the potential to spread and 
invade surrounding tissues [1].  Cancer is the second leading cause of death in the US and 
worldwide, accounting for 16% of deaths worldwide in 2015 [2].  About 1.7 million new cases 
of cancer and about 609,640 deaths have been estimated in the US for the year 2018 [1].  Of 
more than 100 types of cancers affecting humans, breast cancer is the most common cancer 
among women and is the second leading cause of death in women, exceeded only by lung cancer 
[3].  Clinically, breast cancers can be divided into various subtypes by stage, pathology, grade or 
the expression level of specific receptors [4, 5].  Triple negative breast cancer (TNBC), a subtype 
accounting for approximately 15% to 20% of all breast carcinomas, is defined by the lack of 
expression of the estrogen receptor (ER), the progesterone receptor (PR) and the human 
epidermal growth factor receptor (HER2 /neu) [4, 6, 7].  It was reported that TNBC is much 
more common in younger women and in women of African ancestry in addition to exhibiting 
more BRCA1 mutations [8].  Although the population of TNBC is not the largest among various 
subtypes of breast cancer, the prognosis for TNBC remains the poorest because it is more 
aggressive and not responsive to targeted therapies that are effective to other subtypes of breast 
cancer.  Among breast cancer patients, those with TNBC have the poorest prognosis and the 
shortest life span [7]. 
1.1.2 Treatment choices and chemotherapy.  Patients with TNBC cannot benefit from 
hormone therapy because the cancer is ER/PR-negative; they cannot benefit from Herceptin-
based therapy because the cancer cells are HER2-negative.  Therefore, surgery, radiation therapy 
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and chemotherapy, individually or in combination, are the only available options for the TNBC 
patients.   
Surgery and radiotherapy are available options to patients with other subtypes of breast 
cancer.  Basically, there are 2 types of breast cancer surgery: lumpectomy and mastectomy, of 
which the aim is to remove the entire tumor from the breast.  Radiotherapy is typically conducted 
in the TNBC patient following the surgery, more often in women having lumpectomy (breast 
conserving surgery).  It was reported that TNBC patients with the BRCA1 gene mutation are 
potentially highly radiosensitive and benefit more from the radiotherapy [9].   
Chemotherapy, individually or in combination with surgery or radiotherapy is 
predominantly given to the patients with both early stage and advanced TNBC although there are 
no standard guidelines for TNBC chemotherapeutic treatment [5, 10].  Generally, there are 
different categories of chemotherapies based on the mechanism, including microtubule 
stabilizers, DNA replication inhibitor, cell proliferation inhibitor and targeted therapies [10, 11]. 
Microtubule stabilizers are a group of microtubule-targeting agents that bind to 
microtubules and increase the quantity of cellular microtubules by breaking the dynamics of 
tubulin polymer during the mitotic stage of the cell cycle [12, 13].  Taxanes, including paclitaxel 
and docetaxel, exhibit more potency against TNBCs than receptor-positive breast cancers.  It was 
reported that TNBC patients who received the treatment of fluororacil, epirubicin, and 
cyclophosphamide (FEC) followed by weekly paclitaxel for 8 week benefit more than the patient 
receiving FEC only [14].   
Platinum compounds play a major role in treating TNBC.  Carboplatin and cisplatin form 
crosslinks within and between double-stranded DNA, which inhibits DNA replication.  Hence, 
platinums can overcome the DNA repair cascade caused by the BRCA mutation, making them 
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the primary option for the TNBC patient with BRCA mutation [15].  Although Zhang et al. 
reported the cisplatin-based treatment have the best efficacy against TNBC, the platinums are 
still recommended to be used with other chemotherapeutic drug to achieve better efficacy [16].   
Anthracyclines, such as doxorubicin and epirubicin, are some of the most common and 
most active drugs for the breast cancer treatment.  It was found that the pathologic complete 
response (pCR), disease-free survival (DFS) and overall survival (OS) are improved with the use 
of neoadjuvant chemotherapy, in which anthracycline-based regimen is frequently utilized.  
Carey et al. reported that doxorubicin and cyclophosphamide treatment showed better clinical 
sefficacy on TNBC patients than non-TNBC patients [17].  In addition, DNA damage caused by 
anthracycline can also bypass the effect of BRCA mutation [18].  57.1% vs 29% pCR rates were 
found between BRCA1 mutated and wild type TNBC patients after being treated with 
anthracycline and taxane regimens, respectively [19]. 
In addition, targeted chemotherapy, which aims at particular growth factor or receptor is 
also widely used in the treatment of TNBC.  Examples of targeted therapy include PARP 
inhibitors, angiogenesis inhibitors, EGFR inhibitors, TK inhibitors and mTOR inhibitors [10].  
Immunotherapy, such as checkpoint inhibitors, has also emerged to improve the outcome of 
advanced-stage TNBC in combination with chemotherapy [20]. 
1.1.3 Doxorubicin: Pros and cons.  Doxorubicin (DOX or DXR) (Figure 1.1), which 
was first extracted from the actinobacteria Streptomyces peucetius var. caesius, is one of the 
most commonly used anthracyclines [21].  DOX belongs to the antibiotic category of cytotoxic 
anticancer drugs [22].  DOX is indicated in the treatment of various cancers including breast 
cancer, ovarian cancer, lung cancer, neuroblastoma, gastric cancer, Hodgkin lymphoma and 
acute lymphocytic leukemia[23-25].  It is administrated by an intravenous injection through 
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catheter to prevent extravasation and is often used in a combination with other chemotherapy 
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C, 59.66; H, 5.38; N, 2.58; O, 32.38  




The cytotoxicity of DOX is cell cycle-nonspecific but peaks in the S phase.  Several 
mechanisms have been proposed to explain the anticancer activity of DOX, of which two major 
ones are widely accepted (Figure 1.2).  One is inhibition of macromolecular biosynthesis by 
intercalation into DNA and another is cell membrane damage through the generation of free 
radicals and reactive oxygen species (ROS) [27-29].  The intercalation of DOX into DNA causes 
inhibition of the function of the topoisomerase II (TOP II) complex, an enzyme responsible for 
relaxing supercoils in DNA during transcription [27, 30, 31].  Regarding free radical generation, 
DOX is reduced by the ubiquitous oxidoreductases to form unstable DOX-semiquinone radicals, 
which carry out one-electron reduction of molecular oxygen to generate reactive oxygen species 
(ROS) that lead to lipid peroxidation and membrane damage, DNA damage and oxidative stress, 






Figure 1.2.  Mechanism of action of doxorubicin (candidate genes involved in the action of 




After the approval of DOX in 1974, it took 20 years to see the approval of paclitaxel  for 
metastatic breast cancer [34].  The ability to arrest the cell cycle at all stages and the broad-
spectrum antineoplastic activity makes DOX most widely used in cancer therapy.  However, the 
clinical use of DOX is still restricted by several side effects (Table 1.1), especially dose-
dependent cardiotoxicity [35, 36].  The development of liposomal DOX was based on the 
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rationale, that the DOX encapsulated inside liposome cannot extravasate in areas with tight 
capillary junctions such as heart muscle but can escape where the vasculature is not tighty 
jointed such as in solid tumors [37].  Hence, the first nanotechnology-based drug Doxil® carries 
less cardiotoxicity than the free DOX, and was approved in 1995 [38]. 
 
Table 1.1.  Adverse effects associated with doxorubicin [37] 
Category   Adverse events 
Hematologic Bone marrow depression especially of 
neutrophils and platelets 
Dermatologic Photosensitivity, itching, rash 
Gastrointestinal Nausea, vomiting, oral ulceration, lopecia, 
diarrhea 
Cardiovascular 
        Acute cardiotoxicity 
 
 
       Chronic 
cardiotoxicity 
 
Tachycardia, hypotension and various 
Electrocardiography (ECG) changes due to 
arrhythmia 
Cardiomyopathy leading to congestive 
cardiac failure 





Another practical reason leading us to select DOX as a cargo drug is its unique spectral 
property.  DOX is a fluorescent molecule which is typically excited at 485 nm and emits high 
quantum yield fluorescence between 560 - 590 nm.  Such a long wavelength allows us to 
conduct visualized experiments to investigate the DOX’s distribution in vitro.    
1.1.4 Barriers in drug delivery to TNBC.  TNBC is considered as a malignant solid 
tumor, which is an abnormal growth of cells that forms a mass in a solid tissue.  The 
physiological characteristics of a solid tumor (Figure 1.3) are distinct from normal tissue, 
including neovasculature, interstitial pressure, and multiple gradients of nutrients, oxygen and 
therapeutic agents.  Newly formed blood vessels are structurally and functionally abnormal [39].  
The distribution of blood vessels in a solid tumor is also heterogeneous, ranging from well 
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perfused periphery to avascular necrotic core, which increases the difficulty to sufficiently 
deliver anticancer agents into all the cancer cells.  In addition, the high interstitial pressure in 
tumors compared to normal tissues leads to a net outward flow from the core of the tumor.  It 
was reported that the elevated interstitial fluid pressure of a solid tumor may aggravate the 
gradients of angiogenic factor that are released into the surrounding tissues [40].  Furthermore, 
the abnormal lymphatic function, the elevated interstitial hydraulic conductivity as well as the 
collapse of tumor lymphatic drainage are the main causes of the interstitial fluid pressure inside 
the solid tumor [40].     
To exert its activity, an anticancer drug has to avoid quick clearance and distribute 
sufficiently to the blood vessels of a tumor, then permeate through the tumor blood vessels 
efficiently, then translocate through the interstitial matrix to penetrate deep into the tumor [41].   
The extravasation and the penetration are largely affected by the physiochemical properties of 
the compound, such as size, charge, and solubility in water and lipids.  The penetration and 
transport through the tumor interstitium are mainly controlled by diffusion, which is governed by 
concentration gradient.  However, ionization of the drug molecule in the tumor 
microenvironment will increase its interaction with the extracellular matrix and thus hamper 
diffusion.  One example would be doxorubicin, a weak base, getting protonated and then stuck in 
the acidic organelles and interstitium.  The transport of larger molecules is mainly governed by 
convection, which depends on the hydraulic conductivity and pressure difference.  Specifically, 
extravasation of macromolecules will be drastically decreased by the high interstitial fluid 
pressure of the solid tumor.  Furthermore, the well interconnected structure of extracellular 
matrix, such as collagen, will decrease the penetration of high-molecular-weight drugs [42].  All 
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those characters in solid tumor are all present in TNBC and create a dreadful barrier to the 
delivery of anticancer drugs against TNBC. 
 
 




1.2 Strategies for Effective Delivery of Doxorubicin to Solid Tumors 
1.2.1 Targeted delivery.  An ideal drug delivery system has to overcome the above 
mentioned barriers in order to improve therapeutic efficacy and to minimize adverse effects of 
the cargo drug.  Targeted drug delivery provides one of the solutions by modifying the 
pharmacokinetics profile, especially the distribution of anticancer agents.  Generally, there are 
two broad classes of drug targeting, namely passive targeting and active targeting [44, 45]. 
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1.2.1.1 Passive targeting.  Passive targeting, also called physical targeting, achieves the 
desired accumulation of therapeutic agent at the target site by catering the physicochemical 
properties of the drug delivery system to the distinctive characteristics of the pathologic 
tissue/organ.  The enhanced permeation and retention (EPR) effect, one of mechanisms of 
passive targeting (Figure 1.4), was proposed in 1986 as an innovative strategy to deliver 
macromolecular drugs to tumors [46].  The enhanced permeation of nanocarriers or 
macromolecules at the tumor site is caused by tumor vascular leakage while the enhanced 
retention occurs due to the impaired lymphatic drainage within neoplastic tissues [47].  The cut-
off size of the permeabilized vasculature varies, but 200 nm in diameter or below is generally 
accepted for the solid tumor vasculature [48].  Nevertheless, an extended period of circulation in 
the blood is required for this type of drug delivery system to achieve sufficient accumulation in 
the tumor.  Besides keeping the molecular weight above 40 kDa to circumvent renal filtration, 
the common way to keep the nano-drug delivery system in the blood stream is to disguise them 
by grafting their surface with polyethylene glycol (PEG).  This hydrophilic polymer minimizes 
the adsorption of serum proteins to prevent opsonization and thus hinder their recognition and 
clearance by the reticuloendothelial system (RES) [49].  Generally, the higher average molecular 
weight of PEG leads to longer systemic circulation time, except that liver clearance is found to 
be enhanced when the average molecular weight of PEG goes over above 50 kDa [50].  In 
addition, prolonged circulation makes it possible to maintain therapeutic concentrations of drug 








It must be noted that there are several challenges in passive targeting for anticancer drug 
delivery.  First, the EPR effect varies by the different structures of various tumors.  For instance, 
hepatic and renal carcinoma show relatively strong EPR effect due to the high vascular density, 
while pancreatic and prostate cancers show less EPR effect [46].  In addition, the heterogeneity 
within one solid tumor also creates an imbalance of the EPR effect.  It is reported that the central 
necrotic area of metastatic cancers doesn’t exhibit the EPR effect due to the lack of vasculature 
[52, 53].  This phenomenon makes penetration the limiting step to achieve the desired 
therapeutic efficacy.  Furthermore, tumor growth rate and tumor size in animal models are not 
comparable to that in humans, leading to differences of EPR effect between tumor and tumor 
xenografts [54].  Rodent tumor models always have tumors at least 5 mm in diameter during the 
late stage and a larger tumor is more likely to have hypovascular areas in the necrotic core.  
Moreover, the resistance of the capillary wall to the move of macromolecules or drug delivery 
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system getting into tumor interstitial space, which is significantly greater than subsequent 
resistance, is a noticeable factor that affects the outcome of the EPR effect [55].   
1.2.1.2 Active targeting.  In general, active targeting involves coupling specific targeting 
ligands to the surface of the drug carrier so that it can selectively bind to target receptors 
expressed on the surface of particular cell, tissue or an organ [56, 57].  The strong interaction 
between the ligand and receptor is so selective that the unwanted non-specific binding in 
peripheral tissues and toxicity will be reduced.  Because some receptors manifest higher 
expression in the tumor cells or tumor vasculature cells than normal cells, a solid tumor is highly 
likely to get benefits of active targeting therapy.  It is also reported that the activation of 
receptor-mediated endocytosis by such specific binding can suppress multidrug resistance 
because it circumvents drug efflux by P-glycoprotein [58].  Tremendous effects were put into 
developing novel targeted delivery systems for diagnostic and therapeutic applications in various 
diseases.  The active targeting ligands that are exploited in those systems include antibodies, 
antibody fragments, aptamers, peptides, proteins and some small molecules which are known as 
receptor ligands [59].  Currently, antibody-drug conjugates (ADCs), which currently represent 
the leading class of biopharmaceutical drugs, is an eminent example of the active targeting 
strategy.  All the four approved ADC products are utilized to treat various types of cancer, which 
suggests the great clinical response to this strategy of treating cancer.  Unfortunately, TNBC is 
so far known to have no potential target receptor to take advantage of active targeting. 
1.2.2 Liposomes.  As one of the nanocarriers, liposomes are nano-sized vesicles 
composed of amphiphilic molecules such as phospholipids, which form a closed bilayer structure 
that encloses a central aqueous compartment [60-62] (Figure 1.5).  Liposomes have a spherical 
shape with the size ranging from 20 nm to a few microns in diameter.  Typically, the hydrophilic 
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drug molecules can be encapsulated in the aqueous core while lipophilic drugs can be 
incorporated in the lipid bilayer (Figure 1.6), which enables liposomes to deliver a variety of 
cargo molecules including small molecules, proteins, nucleotides and even plasmids [61].   
Liposomes can be categorized into the following types based on the numbers of concentric lipid 
bilayers and the size:  multilamellar vesicle (MLV), small unilamellar vesicle (SUV) and large 
unilamellar vesicle (LUV) [63].   
From the perspective of biomedical application, liposomes consist of biocompatible 
material which won’t cause severe allergic or toxic reactions and will eventually be broken down 
through biological pathways [64].  Liposomes can protect the entrapped cargo molecules, 
especially proteins and nucleotides from the inactivating effect of the physiological media [44].  
It was also reported that liposomes can fuse with the cell surface to deliver agents into cell [65].  
From the perspective of clinical application, liposomes are capable of altering the bio-
distribution and the rate of clearance of the contents entrapped, which results in the drastic 
change of the pharmacokinetic parameters [64].  The physicochemical properties of the 
liposome, such as size, surface charge and steric stabilization are the main factors affecting the 
pharmacokinetic profile.  Besides these features, the surface of the liposomes can be grafted with 
various molecules to enhance their stability in blood circulation and/or to increase their specific 
targeting to certain cells/tissues.  The first liposomal pharmaceutical product Doxil® (Janssen 
Products, LP, Horsham, PA) was approved by the FDA to treat Kaposi’s sarcoma and breast cancer 
in 1995 and 2003, respectively [38, 66].  There are currently more than ten marketed liposomal 





Figure 1.5.  The self-assembly of individual amphiphilic lipids (a) to bilayer (b) and then to 
closed liposomes (c).  A single bilayer is typically ~5 nm thick and consists of neatly arranged 
individual lipid molecules with their hydrophilic heads facing the internal and external aqueous 





Figure 1.6.  Drug loading in liposome:  soluble hydrophilic drugs are entrapped into the aqueous 
interior of the liposome ( ), while poorly soluble hydrophobic drugs are localized in the 






1.2.2.1 Conventional liposomes.  Conventional liposomes, sometimes termed classical 
liposomes or 1st generation liposomes, are made up of neutral and/or negatively charged 
phospholipids and cholesterol.  Some of these formulations are on the market already, such as 
Ambisome® (Gilead Sciences, Foster City, CA), Daunoxome® (Gilead Sciences) and Myocet® 
(Elan Pharmaceuticals Inc., Princeton, NJ).  It was observed that conventional liposomes are 
rapidly captured by cells of the RES and eliminated from blood circulation, leading to their 
relative short half-life [68].  This in vivo attribute of conventional liposomes was exploited to 
develop antiparasitic and antimicrobial drugs in order to treat infections because both the 
liposomes and the pathogen cells accumulate to the RES [69, 70].  It was also reported that 
increasing size of conventional liposomes would enhance uptake in the RES, primarily in the 
liver, leading to more rapid hepatic clearance [71].  Furthermore, it was found that drug leakage 
from conventional liposomes is associated with their interaction with high and low density 
lipoproteins in the plasma, especially when the conventional liposome does not carry cholesterol 
in the lipid membrane [72, 73].  As mentioned above, the application of conventional liposome is 
limited when the target site is beyond RES. 
1.2.2.2 Stealth liposomes.  The incorporation of saturated phospholipids with high 
transition temperature (Tm) and cholesterol into the bilayer structure still cannot fully overcome 
the in vivo stability issue caused by opsonization.  In order to target tissues other than the RES 
system, liposomes need to minimize interaction with the RES so as to prolong their half life in 
blood circulation.  Several strategies in this regard have been developed.  The surface of the 
liposome can be grafted with monosialoganglioside [74] to generate new “stealth liposomes” 
with a more hydrophilic surface [75] that decrease the liposomes’s interaction with RES.  The 
most popular and successful method to generate “stealth liposomes” is to coat the liposome 
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surface with hydrophilic polymers, such as poly (ethylene glycol) (PEG).  The basic mechanism 
is that the hydrophilic polymer molecules with a flexible chain occupy the space adjacent to the 
surface of liposome and thus form a steric protective layer to hinder the binding of other 
macromolecules such as opsonin, thereby slowing down the liposomes’ recognition by the RES 
and subsequent clearance [62, 64, 72].  Moreover, it was reported that the PEG chains on the 
liposome surface provide strong repulsion between membranes to prevent liposome aggregation, 
thus improving the stability of formulations [76].  In this way, the EPR effect can be enhanced 
due to the sufficient time available for the stealth liposomes to accumulate in the solid tumor, 
which results in improvements in the therapeutic outcomes compared to conventional liposome.  
As an example, Doxil® as a representative of stealth liposome was approved to treat AIDS-
related Kaposi's sarcoma. 
1.2.2.3 Stimuli-responsive liposomes.  It must be kept in mind that only the drug 
molecules that are released from liposomes can exert their biological function.  Thus, the 
therapeutic efficacy of liposome formulations can improve only when the rate of drug release 
from liposomes is elevated at the target tumor [77, 78].  The stability of PEGylated liposomes 
may not always favor more biological effect, especially if it does not increase the distribution of 
the cargo drug molecules inside the target cells.  An ideal liposomal drug delivery system should 
remain stable during blood circulation until it is delivered to the disease site, and then elevate the 
release of its cargo drug molecules in response to a specific stimulus at the target site.  The 
stimulus can be internal or external.  The former is endogenous stimuli presented in various 
physiological environments, such as low endosomal pH [79], raised temperature at inflammatory 
tissue [80] and specific enzymes in a particular microenvironment [81].  The latter is the stimuli 
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from external sources, which include ultrasounds [82], light [83], magnetic field [84] and electric 
field [85].  Typically, the application of external stimuli requires particular facilities.   
If a stimuli-responsive lipid component is incorporated into the stealth liposome, the 
liposome can then be developed into a “smart” delivery system to achieve controlled release as a 
“magic bullet”.   
 1.2.3 pH-sensitive lipids and fliposomes.  Among the above mentioned stimuli, pH 
gradients have been widely investigated because they are present at various organs, tissues and 
cell levels within body (Figure 1.7) [86].  It is widely recognized that the acidic extracellular 
microenvironment is the most prevalent attribute among various types of tumors except for blood 
carcinomas.  Generally speaking cancer cells have an intracellular pH (pHi ) of 7.4 and a lower 
extracellular pH (pHe) of ~6.7 while the reverse pattern is observed in normal cells (pHi= ~7.2 
and pHe= ~7.4) [87].  As the solid tumor grows, cancer cells become farther from the basement 
membrane and vasculature, leading to the low oxygen supply.  The high consumption of energy 
required for cancer cell survival is compensated by the upregulation of glycolysis [88-90].  
Simultaneously, HIF-1α expression is activated and promotes the activation of multiple genes 
including those encoding pH regulators, leading to the overexpression of Na+ -H+ exchanger 
NHE1 of the SLC9A family and the monocarboxylate - H+ efflux cotransporters MCT1 and 
MCT4 of the SLC16A family [87, 88] (Figure 1.8).  All these pathways, together with the 
absence of lymphatic drainage contribute to the acidification of the tumor microenvironment.  It 
was reported that decreased pHe is associated with a tumor’s escape from immune detection and 
eventually cancer progression and metastasis [90, 91].  Furthermore, at subcellular level the pH 




Figure 1.7.  Examples of different physiological pHs available for pH-sensitive drug delivery 
targeting.   a) Targeting at the organ level: the GI tract is characterized by a pH gradient.  b) 
Targeting at the tissue level: solid tumors exhibit an acidic extracellular microenvironment.  c) 
Targeting at the cellular level: endo-lysosomes are more acidic compared to the cytoplasm 









As mentioned above, pH gradient could be an excellent trigger to elevate the release of 
therapeutic agent from stimuli-response liposomes.  Most of the reported work on pH-sensitive 
liposomes takes advantage of the dramatically more acidic environment of endosomes/lysosomes 
[93, 94].  While the pH in the tumor interstitium is slightly lower than the one in blood, it is 
rarely below 6.5, which makes it difficult for the pH-sensitive liposomes to release more drugs 
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[95].  Many approaches have been tried to render stealth liposomes pH-sensitive, including 
incorporation of pH-sensitive fusogenic peptides [96, 97], coating the liposomes with polyanions 
[98, 99] and incorporation of the phase transition lipid PE [100].   
Various pH-sensitive lipids were designed and synthesized previously in our lab [101, 
102].  A conformationally controlled molecular switch has been designed to destabilize the 
liposome membrane in response to a pH drop and was reported by our group and collaborators 
[103][104].  The mechanism of the membrane destabilization is that an intramolecular hydrogen 
bond between the protonated amine group and its neighboring hydroxyl group induces a 
conformational change of the cyclohexane ring in the lipid, leading to the axial positional 
transformation of the lipid tails [105] (Figure 1.9).  In stealth liposome comprising such pH-
sensitive lipids, the conformational switch can destabilize the lipid bilayer, thus increasing the 
rate of content release (Figure 1.10).  Lipids with this kind of conformational switch are named 
“flipids” and the liposomes containing flipids are called “fliposomes” [106-108].  In order to 
fulfill the prerequisite of stability, flipids with saturated hydrocarbon chains at the length of 16 
carbons were selected to develop fliposomes for the treatment of TNBC.  With preliminary data, 
flipids with amine group of morpholine (estimated pKa in methanol = 4.9) and azetidine 
(estimated pKa in methanol = 6.8) (Figure 1.11) fit into the narrow range of pH gradient in tumor 
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Figure 1.11.  Chemical structure and Estmated pKa in methanol of MOR-C16 and AZE-C16 
[104] 
 
1.3 Hypothesis and Specific Aims 
Based on the foregoing review of the literature, we hypothesize that pH-triggered release 
from liposomes can improve physical targeting, consequently the efficacy of doxorubicin against 
triple negative breast cancer.  Accordingly, select fliposomes loaded with doxorubicin were 
prepared by different methods and characterized in vitro to investigate the triggered release in 
response to the acidic pH that mimics the acidic tumor microenvironment.  The optimization of 
select fliposome was conducted to further fulfill the prerequisite for in vivo application.   
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Afterwards, the anticancer efficacy of the resultant fliposomes was evaluated in both 2D 
monolayer TNBC cells and in 3D MCS of TNC cells in vitro.  Finally, the anticancer activity of 
select flipsomes were also evaluated in an orthotopic xenograft model of TNBC.  The 
comparison of anticancer efficacy in vitro and in vivo between fliposome and corresponding non 
pH-sensitive liposomes was conducted to evaluate the improvement due to pH-triggered release. 
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Chapter 2: Preparation and Characterization of pH-sensitive Fliposome 
 
2.1 Introduction: Strategies to Prepare pH-sensitive Liposomes 
It is widely known that liposomes are mainly composited with natural and/or synthetic 
lipids, which are classified as amphiphilic molecules.  Once those molecules are exposed to 
aqueous solution, they tend to form aggregated complexes so as to minimize entropically 
unfavorable interactions between their hydrophobic moieties and the surrounding water 
molecules.  Numerous techniques and methods have been developed to prepare liposome 
formulations since their discovery by Bangham et al in 1965 [109].  The formation of liposomes 
requires a sufficient amount of energy to form a thermodynamic system, therefore dispersion is 
the key step with various techniques.  Accordingly, liposomal preparation falls into two 
categories: mechanical dispersion methods and solvent dispersion methods [110-113].    
The mechanical dispersion methods include the following types: thin-film lipid 
hydration, sonication, freeze-thawing, and membrane extrusion.  These methods could be 
performed individually or in combination depending on the nature of the formulation 
components.  Thin-film hydration was originally invented by Bangham [109], in which the 
mixture of lipids was first dispersed in an organic solvent.  Then the solvent was removed under 
vacuum to obtain a thin layer of lipid film deposited at the bottom of flask.  Hydration buffer was 
added under agitation at a temperature above the lipid transition temperature (Tm) [109].  By this 
method, multilamellar liposomes (MLVs) with size ranging from 0.5 µm to 5 µm could be 
obtained.  Typically, further size reduction was required to attain smaller and uniformly sized 
formulations.  Sonication is one of the methods to reduce the size.  A bath or probe tip sonicator 
is required for producing small unilamellar vesicles (SUV).  However, sonication can degrade 
the lipids and the encapsulated compounds, in addition to the drawback of decreasing the 
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liposomes’ internal volume [110].  The process of quick freezing and slow thawing forms 
unilamellar vesicles by reorganizing the structure of SUV[114, 115].  Extrusion through 
polycarbonate filters with different pore size above Tm is another method widely implemented to 
reduce the liposome size.   
The commonly used solvent dispersion methods are solvent injection and reverse phase 
evaporation [113].  The solvent injection method involves dissolution of the desired lipids into 
an organic solvent (ethanol or ether), then the injection of the organic solvent into aqueous media 
to form the liposomes.  The difference between the two organic solvent is the method to remove.  
Ether is removed by evaporation at elevated temperature or under reduced pressure, while 
ethanol is removed by dialysis or diafiltration because it is miscible with water.  Both of the 
injection methods have the disadvantage of heterogeneity of the resultant formulation.  The 
reverse phase evaporation method results in the fusion of micelles into liposomes during the 
evaporation of the organic solvent.  When the gel eventually collapses after evaporation, some of 
the phospholipids form bilayer structures around the residual micelle to form liposomes.  This 
method has the advantage of high loading efficiency by creating a higher aqueous space-to-lipid 
ratio, while carrying the disadvantage of possible degradation of the lipids and the loading 
content by sonication during the micelles’ formation [112, 113].  Solvent dispersion could be 
combined with appropriate mechanical dispersion to form smaller and more homogenous 
liposomes. 
In addition, new large-scale liposome preparation techniques, such as spray-drying, 
freeze-drying and microfluidics, have emerged in response to the demand for industrial scale 
production.  Several modified ethanol injection methods have been applied to large scale 
liposome manufacturing [116].   
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In this study, a sequential combination of mechanical dispersion methods including lipid 
film hydration, freeze-thawing, and finally membrane extrusion was well-established in our 
group.  Moreover, we have established the ethanol injection method because it is widely used in 
industrial production.  The procedure of the method includes ethanol injection followed by 
diafiltration.  In addition, sonication was also involved before drug loading in case that the size 
of resultant after extrusion was not small enough.  The aim of this chapter’s studies is to establish 
robust preparation method of DOX-loaded fliposome. 
2.2 Materials and Methods 
2.2.1 Materials.  The lipids 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-
distearoyl-sn-glycero-3-phosphocholine (DSPC), N-palmitoyl-sphingosine-1-
(succinyl[methoxy(polyethylene glycol)2000]) (PEG-ceramide (2000)), 1,2-dipalmitoyl-sn-
glycero-3-phosphoethanolamine-N-[azido(polyethylene glycol)-2000 (DPPE-PEG (2000)) were 
purchased from Avanti Polar Lipids, Inc.  (Alabaster, AL, USA).  Cholesterol, copper(II) D-
gluconate, octaethylene glycol monododecyl ether (detergent OGME/C12E8), Dowex® 50WX-
4, 2-Amino-2-(hydroxymethyl)propane-1,3-diol (Tris) and triethanolamine (TEA) were 
purchased from Sigma-Aldrich.  Doxorubicin Hydrochloride was purchased from Biotang 
(Waltham, MA, USA).  Calcein, sucrose and 2-[4-(2-hydroxyethyl)piperazin-1-yl]-
ethanesulfonic acid (HEPES) were purchased from Fisher Scientific.  All other organic solvent 
and chemicals were purchased from Sigma Aldrich, Fisher Scientific or VWR.   
2.2.2 Preparation of DOX-loaded liposomes. 
2.2.2.1 Preparation of DOX-loaded liposomes by thin-film hydration coupled with 
freeze-annealing-thawing.  Generally, empty liposomes were prepared with thin-film hydration, 
followed by extrusion based on prior reports [102, 108].  Chloroform and dichloromethane 
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solutions of various lipids were mixed in a 25 mL round bottom pear-shaped flask.  The traces of 
organic solvent were removed by evaporation on a Buchi rotavapor and further drying in high 
vacuum overnight at room temperature.  The thin-film of lipids at the bottom of the flask was 
hydrated with 30 mM HEPES buffer (pH 7.4) containing 300 mM MnSO4 or 375 mM TEA 
buffer (pH 8.0) containing 100 mM Cu-Gluconate in a 60 °C water bath.  The flask was filled 
with argon followed by parafilm sealing.  Intermittent agitation and vortexing were applied to 
facilitate the hydration to obtain a liposome suspension of 20 mM total lipids.  The liposome 
suspension was followed by freeze-annealing-thawing procedure (sequentially immersion in 
liquid nitrogen, ice-and-water mixture and 60 °C water bath until the temperature was 
equilibrated respectively) for seven times.  Then the liposome suspension was sequentially 
extruded at least eleven times through 400 nm, 200 nm and 100 nm polycarbonate membranes 
(Nucleopore Corp., Pleasanton, CA, USA) using a hand-held Mini-extruder (Avanti Polar Lipids 
Inc., Alabaster, AL, USA) or three times using a high-pressure nitrogen Lipex® extruder 
(TRANSFERRA Nanosciences Inc., Burnaby, B.C., Canada) at 60 °C.   
In order to establish a transmembrane metal salt gradient, the extruded liposomes were 
run through a Sephadex G-75 size exclusion column (SEC) (Sigma Aldrich, St. Louis, MO,USA) 
which was pre-equilibrated with isotonic buffer containing 5 mM HEPES and 140 mM saline 
(pH 7.4) or 10 mM Tris in 10% sucrose solution (pH 8.0).  Doxorubicin was dissolved in the 
same isotonic buffer at the concentration of 2 or 4 mg/mL.  After passing through SEC, the 
empty liposome suspension was promptly mixed with the previously described DOX solution in 
1:1 volume/volume ratio and incubated at 60 °C for 40 minutes [117].  The cation-exchange 
resin Dowex® 50WX-4 (Sigma Aldrich, St. Louis, MO, USA) was pretreated as previously 
reported [118] and was mixed with liposome preparation at weight ratio of resin: DOX = 60 :1 
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and gently shaken for 25 minutes at room temperature.  During the incubation period, the 
positively charged, free DOX binds to the Dowex resin, while the entrapped DOX remains 
associated with the liposomes.  The Dowex was removed from the DOX-loaded liposomes by 
filtration of the mixture through 25 gauge syringe needle.  The resultant liposome preparations 
were stored at 4 °C in brown glass vials that were filled with argon until further studies.    
2.2.2.2 Preparation of DOX-loaded liposome by ethanol injection.  The desired lipids 
were dissolved into absolute ethanol above the lipids transition temperature (60°C).  The 30 mM 
HEPES buffer (pH 7.4) containing 300 mM MnSO4 or 375 mM TEA buffer (pH 8.0) containing 
100 mM Cu-Gluconate was equilibrated at 60°C in a hot water bath.  Then the lipid ethanol 
solution was injected into aqueous media.  Liposomes formed spontaneously with mild shaking 
and agitation.  The solution was sequentially passed 3 times through polycarbonate membranes 
of 400, 200, 100 nm pore size using a high pressure nitrogen Lipex® extruder (TRANSFERRA 
Nanosciences Inc., Burnaby, B.C., Canada) at 60°C.  The unloaded MnSO4/Cu-Gluconate were 
removed by hollow-fiber diafiltration (MicroKros Spectrum Laboratories, Inc., Rancho 
Dominguez, CA, USA) to establish the transmembrane metal salt gradient and to eliminate 
ethanol from the formulation out of safety concern.  The resultant liposomes were concentrated 
by hollow-fiber diafiltration to a lipid concentration of 15~20 mM, then mixed with the 
previously described DOX solution in 1:1 volume/volume ratio and incubated at 60 °C for 40 
minutes.  Purification was as described in 2.2.2.1. 
2.2.3 Preparation of liposomes encapsulating calcein.  Chloroform and 
dichloromethane solutions of various lipids (Table 2.3) were mixed in a 25 mL round bottom 
pear-shaped flask.  The organic solvent was removed by evaporation on a Buchi rotavapor 
followed by further drying in high vacuum overnight at room temperature.  The thin-film of 
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lipids at the bottom of the flask was hydrated with 100 mM Calcein (pH 7.4) in a 60 °C water 
bath.  The flask was filled with argon, capped and sealed with parafilm.  Intermittent agitation 
and vortex were applied to facilitate the hydration and obtain a liposome suspension of 20 mM 
total lipids.  The liposome suspension was freeze-annealing-thawing (sequentially immersion in 
liquid nitrogen, ice-and-water mixture and 60 °C water bath until the temperature was 
equilibrated respectively) for seven times.  Then the liposome suspension was sequentially 
extruded at least eleven times through 200 nm and 100 nm polycarbonate membranes 
(Nucleopore Corp., Pleasanton, CA, USA) using a high pressure nitrogen Lipex® extruder 
(TRANSFERRA Nanosciences Inc., Burnaby, B.C., Canada) at 60° C.  The resultant liposome 
suspension was passed through a Sephadex G-75 size exclusion column pre-equilibrated with 
isotonic saline containing 5 mM HEPES at pH 7.4 to remove the unencapsulated calcein.  The 
liposome preparations were stored at 4°C in brown glass vials that were filled with argon. 
2.2.4 Physicochemical characterizations of liposomes.  The sizes and ζ-potential of the 
liposome preparations were measured by photon correlation spectrometry and electrophoresis 
mobility under applied voltage, respectively, using Zetasizer ZS 90 (Malvern Instruments Ltd., 
Malvern, UK). 
2.2.5 Quantitation of DOX concentration and encapsulation efficiency of DOX-
loaded liposomes.  An aliquot (10 µL) of DOX-loaded liposome was lyzed with 90 µL lysing 
buffer (90% isopropanol containing 0.075 M HCl) [119].  The fluorescence of solution was 
measured at 485 nm (excitation) and 590 nm (emission) on the Synergy HT microplate reader 
(Biotek, Winooski, VT, USA).  The concentration of DOX was quantified from a calibration 
curve of DOX standard solutions (1, 2, 5, 10, 20, 50, 100 µg/ml) which were operated under the 
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same lyzing procedure.  The encapsulation efficiency (EE) of liposome preparation can be 
calculated by the formula:   
𝐸𝐸 =
𝐷𝑂𝑋 𝑎𝑚𝑜𝑢𝑛𝑡 𝑒𝑛𝑡𝑟𝑎𝑝𝑝𝑒𝑑 𝑖𝑛𝑠𝑖𝑑𝑒 𝑜𝑓 𝑡ℎ𝑒 𝑓𝑜𝑟𝑚𝑢𝑙𝑎𝑡𝑖𝑜𝑛
𝐷𝑂𝑋 𝑎𝑚𝑜𝑢𝑛𝑡 𝑎𝑑𝑑𝑒𝑑 𝑓𝑜𝑟 𝑡ℎ𝑒 𝑑𝑟𝑢𝑔 𝑙𝑜𝑎𝑑𝑖𝑛𝑔
× 100% 
2.3 Results and Discussion 
2.3.1 Size, ζ-potential and polydispersity index (PDI) of liposome formulations.  
After preparation by either thin-film hydration or ethanol injection, the liposomes of various 
compositions presented similar average sizes, smaller than 200 nm after passing through 100 nm 
polycarbonate membranes.  The Polydispersity Index (PDI) of all preparations was lower than 
0.3, which is the key indicator of homogeneity of colloids.  No detectable ζ-potential for all 
formulations suggested neutral charge of the whole system at pH 7.4, which would be expected 
from the neutrally charged lipid components of the liposomes.  The average size, PDI and 
encapsulation efficiency of selected DOX-loaded liposomes are shown in Table 2.1.   
 
Table 2.1.  Size, PDI and EE of DOX-loaded liposomes by different preparation methods 
Liposome Molar Ratio Method Size (nm) PDI. EE (%) 
MOR-C16/DPPC/PEG-DPPE 25/70/5 Thin-film 170.5 0.064 100 
AZE-C16/DPPC/PEG-DPPE 25/70/5 Thin-film 119.8 0.165 86 
MOR-C16/DSPC/Chol/PEG-
Ceramide 
30/40/25/5 Thin-film 189.1 0.188 88 
MOR-C16/DSPC/Chol/PEG-
Ceramide 
30/40/25/5 EtOH Inj. 129.6 0.261 94 
DPPC/Chol/PEG-Ceramide 50/45/5 Thin-film 110.2 0.097 65 






It is widely acknowledged that the size of drug delivery systems has prominent influence 
on their pharmacokinetics profile and tissue distribution [120].  For tumor treatment, 
nanocarriers with only size lower than 150 nm can get into the tumor interstitium by escaping 
from the fenestrated capillaries of solid tumors [120-122].  However, 200 nm is the cut-off size 
for the drug delivery system to take advantage of the EPR effect for tumor treatment [46, 123].  
It is reported that nanocarriers with size ranging from 100 to 150 nm were not able to extravasate 
into normal tissues in kidney, lung and heart [120, 122].  In this study, we have developed robust 
preparation methods and procedures to strictly control the size of liposomes under 200 nm.  
Therefore, all of these liposomes could serve as a viable nano-drug delivery system for 
anticancer treatment. 
2.3.2 Encapsulation efficiency (EE) of DOX-loaded liposomes.  As shown in Table 
2.1, the encapsulation efficiencies of DOX-loaded liposomes achieved 80% to 100% payload 
with concentration ranging from 1 mg/ml to 2 mg/ml by the remote loading method except for 
the conventional liposome with DPPC, Cholesterol and PEG-lipids.   
To be sufficient for animal studies, 2 mg/ml or higher DOX concentration in the final 
formulation was the goal for the all preparations.  For the payload drug Doxorubicin, remote 
loading, also known as active loading, was a well-established procedure to achieve high loading 
efficiency and a high enough concentration.  The transmembrane ion gradient was the driving 
force to pump the payload drug molecules into the liposome aqueous core, while their 
precipitation with either sulfate or metal ion enables high payload retention.  Besides pH 
gradient, ammonium sulfate gradient is the most commonly utilized method in the industry 
manufacture.  Metal salt, such as manganese sulfate or copper gluconate were reported to 
achieve similar loading ability by forming metal-doxorubicin complex which is favored when the 
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intraliposomal pH >6.5 [60, 124].  In this project we utilized either the manganese sulfate or the 
copper gluconate gradient for the remote DOX loading since it circumvented the low pH of the 
ammonium sulfate solution during the drug loading.      
2.3.3 Comparison of different preparation procedure.   
2.3.3.1 Mini-extruder versus nitrogen Lipex extruder.  As shown in Table 2.2, no 
significant difference in the liposome size was observed after using either a mini-extruder or a 
nitrogen Lipex extruder.  The mini-extruder is ideal for a sample whose volume is smaller than 1 
ml.  However, the optimal lipid concentration for this method was 10 mM for better size and 
PDI.  In comparison, the Lipex extruder could be used to prepare 1-10 ml sample in one batch 
and could operate with up to 50 mM lipid concentration to achieve higher drug concentrations in 
the final formulation.  In addition, Lipex extrusion is the industry standard, which can be scaled 
up to prepare 100-800 ml formulations by GMP standards for early clinical development.  In this 
project, early discovery of liposome composition employed the mini-extruders while later larger 
scale liposome preparations for animal studies or formulation optimization employed a Lipex 
extruder. 
 
Table 2.2.  Size, PDI and EE of DOX-loaded liposomes prepared by different extruders 
Liposome 
Lipid Conc.   
(mM) 
Molar Ratio Extruder 
Size 
(nm) 
PDI. EE (%) 
DPPC/Chol/PEG-Ceramide 10 50/45/5 Mini 110.2 0.097 65 




2.3.3.2 Thin-film hydration versus ethanol injection.  There is no qualitative difference 
observed between the size of the liposomes made from the two different methods, as shown in 
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Table 2.1.  Generally thin-film hydration had better PDI value, which indicated better 
homogeneity of the liposome system.  The slight increase of PDI was probably caused by the 
procedure of liposome concentration for drug loading after the diafiltration.  After a composition 
was selected, detailed operation procedure with higher lipid concentration was optimized.  
Because ethanol injection method is more practical and commonly used in industry manufacture, 
it can be scaled up for manufacturing when reproducibility of the method is established. 
2.3.3.3 Manganese sulfate versus copper gluconate.   There is no difference observed 
between two metal salt for remote loading, as shown in Table 2.3.  Because MnSO4 is not 
compatible with alkaline pH and will precipitate at pH = 8.0, copper gluconate is optimal for 
AZE fliposome formulation where the AZE lipid has an amine of pKa 6.8[125]. 
 
Table 2.3.  Size, PDI and EE of DOX-loaded liposomes remote loading with different metal salt 
Liposome Molar Ratio Metal Salt Size (nm) PDI. EE (%) 
MOR-C16/DPPC/PEG-Ceramide 50/45/5 MnSO4 182.4 0.309 100 




     
2.3.4 Characterization of calcein-loaded liposome.  Calcein was utilized as a model 
liposome cargo molecule to verify the release profile.  All the selective liposomes had size range 






Table 2.4.  Size, PDI and EE of Calcein-loaded liposomes 
Liposome Molar Ratio Size (nm) PDI. 
AZE-C16/DSPC/Chol/PEG-Ceramide 33/38/25/5 168.2 0.219 
MOR-C16/DPPC/PEG-Ceramide 25/70/5 144.3 0.150 
DPPC/Chol/PEG-Ceramide 55/40/5 145.4 0.088 




   
2.4 Summary  
The pH-sensitive fliposomes were successfully prepared by thin film hydration and 
ethanol injection.  The traditional proton gradient or ammonium gradient method to remote load 
DOX into liposomes creates acidic environment, which is not compatible with pH-senstivie 
fliposomes.  The metal ion remote loading method was developed to circumvent the increasing 
proton concentration.  Fliposomes carried high encapsulation efficiency (>80%), small mean 
particle size (<200 nm) and small PDI (<0.3), indicating the robust preparation procedure.  The 
quality of liposomes, indicated by size, PDI, varies among different batches, suggesting that 









In the process of product development, the in vitro drug release from an oral dosage 
form, known as dissolution testing, is an essential step to illustrate the quality of the product and 
to forecast its in vivo performance [126].  Dissolution testing was first established back to 1950s 
and accepted by the United States Pharmacopeia (USP) in 1970 [127].  Generally, the 
formulation under the test is deposited into the apparatus and exposed to a releasing media, 
ideally at sink condition.  During certain time of agitation at 37°C, such as stirring of paddle or 
basket, the released drug was sampled and quantified.  There is also a flow-through dissolution 
system known as USP apparatus 4, which is utilized to perform dissolution testing in order to fit 
the requirement for sustained-release formulations.  Through in vitro–in vivo 
correlations/relationships (IVIVC/IVIVR), the dissolution testing could be utilized to predict the 
drug candidate’s performance in vivo and served as critical data for drug development.  For 
instance, a highly soluble drug that was developed in an immediate release formulation could be 
bio-waived because the standardized dissolution testing result is sufficient according to the FDA 
regulatory guidance [126]. 
For complex parenteral formulations, such as liposomes and nanoparticles, the release 
assay is even more important in order to achieve altered pharmacokinetics.  The release assay is 
widely utilized in the therapeutics of oncology.  By means of nano-drug delivery system, 
prolonged circulation of the drug is achieved to enhance intratumoral accumulation of 
chemotherapy agent through the EPR effect.  After the drug’s accumulation inside the target 
tumor, its anticancer activity could be optimized by manipulating the rate of release from the 
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delivery system.  Therefore, the accuracy of the release assay is prerequisite to optimize the 
properties of the delivery system, such as sufficient stability in circulation and quick release at 
the target site. 
In our lab, a release assay based on the fluorophores ANTS/DPX was used to 
characterize liposomes consisting of TACH lipids and to investigate the impact of TACH lipids’ 
amine head groups on the liposomes’ pH sensitivity [102].  The assay mainly served as proof of 
concept for the liposomes’ pH-sensitivity.  For applications in drug delivery, it’s more 
reasonable to evaluate the release with the cargo drug instead of ANTS/DPX.  In addition, the 
newly designed C16 TACH lipids have longer hydrocarbon tails and are used in liposomes in 
combination with saturated phospholipids, which drastically raises the transition temperature 
(Tm) of the resultant liposome formulation.  Therefore, substantial changes of the release profile 
and the response to lower pH are anticipated, which make it essential to develop a more reliable 
release assay for DOX-loaded liposomes under this study.  The aim of this chapter’s studies is to 
establish reliable release assay to evaluate pH-sensitive release of fliposome in vitro. 
3.2 Materials and Methods  
3.2.1 Materials.  Rapid Equilibrium Dialysis (RED) Device was purchased from 
Thermofisher.  Octaethylene glycol monododecyl ether (detergent OGME/C12E8) and Dowex® 
50WX-4 were purchase from Sigma Aldrich.  Acetic acid, D(+)-Glucose, 2-[4-(2-
hydroxyethyl)piperazin-1-yl]-ethanesulfonic acid (HEPES) and 2-(N-morpholino)ethanesulfonic 
acid (MES) were purchased from Fisher Scientific.  Doxorubicin Hydrochloride was purchased 




3.2.2 Equilibrium microdialysis.  Equilibrium microdialysis [128] by the Rapid 
Equilibrium Dialysis (RED) Device (MWCO = 8,000) was utilized to establish release assay 
according to the manufacturer’s recommendations.  Isotonic buffers with different pH were 
prepared as the following: pH 7.4 and 7.0 (100 mM HEPES, 92.6 mM glucose), pH 6.5 and 6.0 
(100 mM MES, 92.6 mM glucose), pH 5.5, 5.0, 4.5 and 4.0 (100 mM acetic acid, 92.6 mM 
glucose).  100 μL of Dox-loaded fliposome or non pH-sensitive liposome preparation was added 
into sample chamber while 300 μL of buffer with different pHs described above was added into 
the buffer chamber.  The RED plate with samples were covered with sealing tape and incubated 
for dialysis at 37°C at approximately 200 rpm on an orbital shaker for overnight (14 hour).  An 
aliquot of the solution in both sample chamber and buffer sample was taken for concentration 
determination.  All measurements are in triplicates.  The percent of DOX released from 
liposomes at different time points was calculated using the following equation. 
% Dox released = [1 −  
(𝐶𝑠 − 𝐶𝑏) × 𝑉𝑠
𝐶𝑖𝑉𝑠
] × 100% 
Where, Vs = Volume of sample chamber, Cs = concentration of Dox in sample chamber, 
Cb = concentration of Dox in buffer chamber, Ci = initial liposomal Dox concentration added to 
sample chamber. 
3.2.3 Indirect resin adsorption method.  Liposomal formulations and a buffer of 
defined pH were added at v/v ratio of 1:7 into an amber glass vial.  The glass vial containing the 
sample was incubated at 37°C at approximately 100 rpm on an orbital shaker overnight (14 
hour).  50 μL of supernatant of the releasing solution was aliquoted and transferred into a 1.5 mL 
centrifuge tube filled with Dowex 50WX4 resin (Dowex : Dox = 60 : 1, wt : wt).  The centrifuge 
tube was agitated for 20 minutes, allowing the released doxorubicin to be completely adsorbed 
by the resin.  Then 10 μL supernatant was aliquoted for analysis after 2 minutes centrifuge at 200 
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rpm.  All measurements are in triplicate.  The percent of DOX released from liposomes at 
different time points was calculated using the following equation. 




Where, Vs = Volume of total solution after incubation, Cs = concentration of Dox of 
supernatant (unreleased), Ci = initial liposomal DOX concentration added, Vi = initial volume of 
liposomal DOX added. 
3.2.4 Fluorescent dequenching method.  In order to capture the kinetic profile of drug 
release from liposomes, a more convenient and rapid release assay than Indirect Resin 
Absorption is necessary.  Doxorubicin has a fluorophore functional group which is excited at 490 
nm and emits fluorescence at 590 nm.  It is suggested that the fluorescence of doxorubicin is also 
self-quenched at high concentrations because of the large overlap between the absorption and the 
emission spectra [129, 130].  Therefore, doxorubicin release could be reflected by the 
dequeching of its fluorescence as the molecules move from its high concentration inside the 
liposome to low concentration outside. 
Each liposomal sample (2 μL) was added into 198 μL of different buffer in a black 96 
well plate.  The fluorescent measurement of doxorubicin as the baseline of no release was 
recorded by the Synergy HT microplate reader (Biotek, Winooski, VT, USA) at 485 nm 
(excitation) and 590 nm (emission) promptly after sample addition.  The plate was sealed with 
tape and incubated at 37 °C on an orbital shaker at approximately 100 rpm.  At incremental time 
points (1, 3, 6, 12, 24, 48 h), the fluorescent intensity of each sample was measured.  At the end 
of experiment, 10 µl detergent (C12E8) was added to fully lyse the Dox-loaded liposomes to 
obtain the fluorescent intensity of complete release (Fx-100).  The release percentage was 
calculated as following, 
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% Dox released =
𝐹𝑡 − 𝐹0
𝐹𝑥−100 − 𝐹0
 x 100% 
Where Ft is the fluorescence intensity of a given time point and F0 is the baseline 
fluorescence intensity upon sample addition, Fx-100 is the fluorescence intensity of liposome that 
is 100% lysed. 
3.2.5 Direct resin adsorption method.  Dowex 50WX4 resin or Bio-beads resin was 
mixed with a buffer-diluted sample of liposomal doxorubicin in an amber glass vial at the ratio 
of resin : Dox = 200 : 1 or 1000:1 (wt : wt), respectively.  The mixture was incubated at 37°C on 
an orbital shaker at approximately 100 rpm.  At incremental time points (0, 3, 6, 12, 24, 36, 48 
h), 10 µl supernatant of each sample was aliquoted and transferred into 90 µl lysing buffer (90% 
isopropanol containing 0.075 M HCl) to quantify DOX.  All measurements were in triplicates.  
The percentage of DOX released from liposomes at different time points was calculated using 
the following equation. 
% Dox released = (1 −
𝐶𝑠𝑉𝑠
𝐶𝑖𝑉𝑖
) × 100% 
Where, Vs = Volume of total solution after incubation, Cs = concentration of Dox of 
supernatant (unreleased), Ci = initial liposomal DOX concentration added, Vi = initial volume of 
liposomal DOX added. 
3.2.6 pH-Triggered release of calcein-loaded fliposmes.  Each sample (20 µl) of 
calcein-loaded liposomes was added into 180 µl of different pH buffer solutions (defined in 
Section 3.2.2) in a black 96 well plate.  The plate was covered with sealing tape and incubated at 
37°C on an orbital shaker at approximately 100 rpm.  At different time points (0, 1, 2, 4, 6, 9, 12, 
24, 36, 48 h), the fluorescence of each well was measured on the Synergy HT microplate reader 
(Biotek, Winooski, VT, USA)  (Ex.  = 495 nm and Em.  = 515 nm).  At the end of experiment, 
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10 µl detergent (C12E8) was added to completely disrupt the bilayer of liposomes and release 
calcein for the 100% release measurement.  All measurements are in triplicate.  The release 




 x 100% 
Where Ft is the fluorescence intensity of a given time point and F0 is the fluorescence 
intensity of initial time point upon sample additiion, Fx-100 is the fluorescence intensity of 
liposome that was 100% lysed. 
3.3 Results and Discussion 
3.3.1 Equilibrium microdialysis.  Selected liposome formulations (DPPC:PEG-DPPE = 
95:5, MOR-C16:DPPC:PEG-DPPE = 25:75:5, AZE-C16:DPPC:PEG-DPPE = 25:75:5) were 
utilized to establish and validated this release assay.  The percentage of pH-triggered release of 
liposomes at four different pH was shown in Table 3.1.   
 
Table 3.1.  Release percentage of selected DOX-loaded liposomes by Equilibrium Microdialysis  
pH DPPC            MOR-C16 AZE-C16 
6.0 41.33 37.30 47.09 
6.5 36.24 28.32 33.62 
7.0 36.83 10.36 40.40 




All selected liposomes showed certain extent of pH-sensitivity by exhibiting elevated 
release at lower pH.  In the meantime, the equilibrium of release could be achieved even within 2 
hours with increased rpm for shaking.  However, large amount of red stains was observed on the 
dialysis membrane, which indicated remarkable mass loss during the dialysis process.  The 
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average recovery rate among all sample is ~ 72.2%.  Furthermore, recovery rate of free 
doxorubicin at concentration 250 μg/ml, 500 μg/ml and 1000 μg/ml was 16.17%, 26.31% and 
33.87% respectively following the same procedure with pH 7.4 buffer.  This phenomenon could 
be explained by the interaction between positive charged doxorubicin and cellulose membrane of 
dialysis tube [131].  Therefore, equilibrium microdialysis was not appropriate for release assay 
of doxorubicin. 
3.2.2 Indirect resin adsorption method.  Select liposomes with different compositions 
Tach-C16:DPPC:PEG-DPPE = 25:75:5) were utilized to establish and validate this release assay.  
The percentage of pH-triggered release of liposomes at defined pH after 14 hour incubation at 37 
°C is shown in the Figure 3.1.  Among all pH-sensitive lipids, MOR-C16 showed the largest 
difference in leakage between physiological environment (pH 7.4) and tumor microenvironment 
(pH 6.0), which made it one of our leading TACH lipids for further investigation.  In addition, 
AZE-C16 has a pKa value around 6.8, which encouraged us to further investigate the lipid for 
































































p H  7 .0
p H  6 .5
p H  6 .0
p H  7 .4
 
Figure 3.1.  Release Percentage of DOX-loaded fliposomes over 14h at defined pHs, 37°C by 




Dowex 50WX4 is a strong cation-exchange resin which could adsorb positively charged 
doxorubicin upon their release from liposomes.  Therefore, Dowex 50WX4 is used to remove 
residual free doxorubicin after active loading of liposomes [132].  For liposome release assay, 
the aqueous solution in the vial is a mixture of released free doxorubicin and unreleased 
doxorubicin entrapped inside of liposome after incubation.  When the mixture solution was then 
agitated with Dowex resin, the released, free doxorubicin would be adsorbed by resin, thus 
allowing the measurement of doxorubicin still trapped in the liposome formulation.  Because the 
fliposomes are typically neutrally charged and have a size (~100 nm) much larger than the pores 
on the resins (~ 10 nm), the resins would not significantly influence the release of the liposomes 
by directly interacting with them.  However, the drawback of this method includes its tedious 
procedure to recover the formulation with the unreleased doxorubicin and its inability to recover 
the whole mass balance. 
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3.2.3 Fluorescent dequenching method.  Selected liposomes with different 
compositions were utilized to establish and validate this release assay.  The kinetics of pH-
triggered release of liposomes at defined pH over 48 hour incubation at 37 °C was tracked and is 
shown in the Figure 3.2.  The pH-sensitive liposomes (MOR-C16:DSPC:Chol:PEG-
Ceramide=30:40:25:5) showed different release profile depending on the pH while the 
conventional liposome (DPPC:Chol:PEG-Ceramide= 50:45:5) maintained the same pattern of 
leakage at all pHs from 4.0 to 7.4.  However, we observed the controversial response to lowered 
pH at two different pH ranges.  As shown in Figure 3.2 over 48 hours and Figure 3.3 at 24 hour, 
fliposome had more leakage at more acidic pH range from 4.0 to 5.5.  However, the trend was 
reversed at pH range from 6.0 to 7.4.   
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Figure 3.2.  Release Percentage of DOX-loaded liposomes (Left: pH-sensitive fliposome MOR-
C16:DSPC:Chol:PEG-Ceramide=30:40:25:5, Right: pH-insensitive liposome DPPC:Chol:PEG-
Ceramide= 50:45:5) over 48h at defined pHs, 37°C by Fluorescent dequenching methods.  Data 










































Figure 3.3.  Release Percentage of DOX-loaded fliposomes (MOR-C16:DSPC:Chol:PEG-
Ceramide=30:40:25:5) at 24h at defined pHs, 37°C by Fluorescent dequenching methods.  Data 




It was reported that Doxorubicin is not stable at neutral pH, 37°C, with a degradation rate 
constant of 0.0174 (1/hour) [131].  The degradation rate decreases as the pH of the buffer 
decreases.  The remaining percentage of doxorubicin (125 µg/ml) after incubation at four pHs, 
37 °C in our experiments conformed with the literature (Table 3.2).  Therefore, the released 
doxorubicin will gradually degrade over the whole process to cause an underestimation of the 
complete release (Fx-100), the more close to 7.4, the more the underestimation.  All these findings 
suggested the limitation of the florescent dequenching method to evaluate release in response to 
different pHs, even though it was the most convenient method to obtain kinetic release profile of 
liposomes if artefacts from the degradation can be mitigated. 
 
Table 3.2.  Doxorubicin remaining in solution at 37°C over 12 h at pH 6.0, 6.5, 7.0 and 7.4 (n = 
3). 
pH 7.4 7.0 6.5 6.0 
Remain % 68.82±1.47 76.94±2.10 89.98±8.35 94.57±3.06 
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3.2.4 Direct resin adsorption methods.  Direct resin adsorption was optimized in order 
to precisely obtain the kinetic release profile of the DOX-loaded liposomes.  The advantage of 
this method is that it balances the ease of the operation procedure and the accuracy of the assay.  
The percentage of pH-triggered release of liposomes (Table 3.3) at defined pHs over 48 hour 
incubation at 37 °C was tracked and shown in the Figure 3.4.  The pH-sensitive liposomes with 
AZE-C16 gave the most response upon the drop of pH, while those with MOR-C16 had less 
change of the release percentage.  The conventional liposome showed no difference of release 
among all pH from 4.5 to 7.4.   
  
Table 3.3.  Composition and characterization of selected DOX-loaded liposomes for direct resin 
adsorption method 
Liposome Mole ratio Size (nm) PDI. 
AZE : Chol : PEG-Ceramide 50:45:5 301.8 0.377 
MOR : Chol : PEG-Ceramide 50:45:5 258.8 0.347 
DPPC : Chol : PEG-Ceramide 50:45:5 112.6 0.122 
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Figure 3.4.  Release Percentage of DOX-loaded fliposomes over 48 h at defined pHs, 37°C by 






Dowex 50WX4 is a strong cation-exchange resin which can adsorb free, positively 
charged doxorubicin.  Bio-Beads SM-2 Resin is composed of neutral, macroporous polystyrene 
beads which are widely used as adsorbent in hydrophobic interaction chromatography.  The 
aromatic rings of doxorubicin could interact with those nonpolar polymeric beads, leading to the 
adsorption.  Both of resins have the pore size below 10 nm, allowing doxorubicin molecules to 
be trapped inside for adsorption.  The fliposomes are typically composed of neutral lipids and 
larger than 100 nm in diameter so the interference by resin on the fliposome release could be 
considered insignificant.  Therefore, the direct resin adsorption method would be an acceptable 
method, by which the release profile would be correctly monitored and the procedure would be 
practical to run large numbers of samples.  However, the drawback of this method was the 
inability to recover the whole mass balance due to practical feasibility. 
3.2.5 pH-Triggered release of calcein-loaded fliposmes.  In order to validate the release 
profile of DOX-loaded fliposomes, we studied the pH-dependent leakage of fliposomes by 
measuring their release of a self-quenching fluorophore, Calcein at pHs 7.4, 7.0, 6.5 and 6.0, 
37°C over time.  The fluorescence of Calcein was measured and then normalized against the 
fluorescence of the lysed liposome sample after adding detergent.  The pH-triggered release of 
calcein over 48 hours from select calcein-loaded fliposomes are shown in Figure 3.5.  The 
fliposomes exhibited increased release at lower pH, while the conventional liposome maintained 
the similar release profile regardless of pH.  The DOX-loaded and calcein-loaded fliposomes 
demonstrated the same the pH-sensitivity trends as shown in Figure 3.6.   
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Figure 3.6.  Release Percentage of DOX-loaded fliposomes and calcein-loaded fliposome after 




Calcein, also known as fluorexon, is a widely used fluorescent probe in cell imaging by 
fluorescent microscopy [133].  Calcein is excited at 495 nm and emits at 515 nm.  Calcein is 
highly water soluble and its fluorescence self-quenches when the concentration reaches above 70 
mM (Figure 3.7), consistent to the literature report [134].  Therefore, calcein has been 
prominently utilized as a model probe for investigating drug release from liposomes and 
liposome-drug interaction.  Generally, calcein, at the concentration above the self-quenching 
concentration, is entrapped inside the aqueous core of liposome by passive loading during 
hydration.  When calcein is release from liposome, it is diluted to give de-quenched and thus 
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elevated fluorescent signal.  Therefore, it is an excellent model to validate our doxorubicin 
release assay on different fliposomes.  Besides calcein, fluorescent dye-and-quencher pairs, such 
as ANTS/DPX are also used in fluorescent assays on the release of liposomes [108, 135].   
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We have studied several release assays for DOX-loaded liposomes, including traditional 
dialysis methods, fluorescent methods and our new resin adsorption methods.  Because of the 
unique chemical properties of the cargo drug, doxorubicin, it is hard to find a direct method to 
measure the released drug in sink condition, which is recognized as the golden standard in 
industry.  Despite certain drawbacks such as the potential interaction between resin and 
formulation and the lack of mass balance, the direct resin adsorption method appears to be the 
most practical and feasible method to kinetically monitor the release profile of pH-sensitive 
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liposomes in vitro.  The advantage and disadvantage of the four release assay methods is 
summarized in Table 3.4.   
  
Table 3.4.  Comparison of release assay methods 
Method Pros Cons 
Equilibrium microdialysis • Quick 
• Small sample sizes 
• Low recovery 
Indirect Resin adsorption • Higher accuracy • Complicated process 
• Systemic error from 
sample size 
Fluorescent dequenching • High throughput • Degradation  
Direct Resin adsorption  • Acceptable error 
• Kinetic monitoring 
• Possible interaction 





Chapter 4: Optimization of pH-sensitive Fliposomes 
 
4.1 Introduction 
In order to maximize the benefit of liposomes for anticancer therapy, many properties of 
such systems need to be optimized.  In addition to triggered release, which is a focus for this 
dissertation, stability, small and homogeneous size, and adequate drug-loading capacity are all 
important properties of liposomes for anticancer therapy. 
Particle size is an essential characteristic of nano drug delivery systems.  The size is 
directly associated with stability, drug payload, release profile as well as pharmacokinetics of the 
drug delivery system [136].  Most importantly, an appropriate size range will allow the 
liposomes to extravasate from blood circulation into the tumor by the EPR effect, but not to be 
cleared by the body [120, 122].  As a reference, market product Doxil® has a size range of 80 -
100 nm [38].  It would be critical to include particle size as a parameter for optimization.   
Polydispersity Index (PDI) is the term to describe the degree of heterogeneity in the size 
distribution of a nanoparticle sample [136, 137].  The value of PDI ranges from 0.0, which 
represents a perfectly uniform sample, to 1.0, which represent a total random distribution of the 
particle size.  PDI values of 0.3 and below are typically accepted to indicate a nanoparticle 
formulation of reasonable quality [137].  From the perspective of liposomes for drug delivery, 
many efficiency and safety issues are related to the size of liposome, such as premature leakage.  
Successful liposome preparations, therefore, should contain homogenous populations of 
nanometer-range vesicle of an optimal size.  The uniformity is another desirable attribute of the 
fliposomes for further application.   
pH-sensitivity and stability are two diagonally opposite properties for quality control.  
Stability is the fundamental requirement for the design of nano-formulations because it prevents 
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many toxicity issues and allows the accumulation of the delivery system at the target site.  It was 
reported that 24-hour circulation is required for the manifestation of the EPR effect [138].  On 
the other hand, pH-sensitivity enables the nano-formulation to respond to the acidic tumor 
microenvironment, pH 6.0.  Balancing the two opposing properties of the fliposomes is the focus 
of this Chapter.   
Drug-loading capacity is an easily overlooked but important property of a formulation.  
The application of any drug formulation requires a minimum loading capacity to eventually 
deliver enough treatment agent.  In our case, it can be optimized to prepare formulation of 
sufficient amount and concentration for the animal studies.  The reference of 2 mg/ml 
doxorubicin concentration in Doxil® is selected as our target.   
The manufacture procedure can be modified to improve the above-mentioned properties.  
Dispersion techniques, such as sonication and extrusion, could be options to optimize the 
preparation.  Lipid-to-drug ratio was also reported to be a key parameter to increase the 
concentration of the drug payload [139].  Lipid composition is the focus of this study to optimize 
the formulation for in vitro and in vivo studies.  The aim of this chapter’s studies is to identify the 
factors influencing the outcomes of EPR effect and to optimize the formulation using 
comprehensive method. 
4.2 Materials and Methods 
4.2.1 Materials.  The lipids 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-
distearoyl-sn-glycero-3-phosphocholine (DSPC), N-palmitoyl-sphingosine-1-
(succinyl[methoxy(polyethylene glycol)2000]) (PEG-ceramide (2000)), 1,2-dipalmitoyl-sn-
glycero-3-phosphoethanolamine-N-[azido(polyethylene glycol)-2000 (DPPE-PEG (2000)) were 
purchased from Avanti Polar Lipids, Inc. (Alabaster, AL, USA).  Cholesterol, copper(II) D-
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gluconate, Dowex® 50WX-4, 2-Amino-2-(hydroxymethyl)propane-1,3-diol (Tris) and 
triethanolamine (TEA) were purchased from Sigma-Aldrich.  Doxorubicin Hydrochloride was 
purchased from Biotang (Waltham, MA, USA).    
4.2.2 Screening design for identification primary factors.   Various liposomes with 
different lipid compositions were prepared by the thin-film hydration methods listed in 2.2.2.1.  
The size and -potential of the liposomes were characterized by the methods listed in 2.2.4.  The 
DOX concentration and drug encapsulation efficiency were determined by the methods listed in 
2.2.5.  pH-sensitivity and stability were evaluated by the direct resin adsorption release assay 
listed in 3.2.5.  The primary factors that control the system were identified by the evaluation of 
colloidal stability and the pH-sensitivity with liposome charaterization. 
4.2.3 Response surface methodology (RSM) for fliposome optimization.  Central 
composite design (CCD) experiments were conducted to visualize the effects of independent 
variables on the select responses which represent the desired properties of the fliposomes.  Two 
variables, percentage of Tach lipid and cholesterol, were identified as major independent factors 
through screening design and used in the design of the experiments by RSM.  Five responses, 
size, PDI, pH-sensitivity, stability and maximum drug loading were selected to represent the 
desired properties of fliposomes, where pH-sensitivity was defined as equation below, 
𝑝𝐻 𝑠𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 (%) =  𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 𝐷𝑂𝑋 % 𝑎𝑡 𝑝𝐻 6.0 − 𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 𝐷𝑂𝑋 % 𝑎𝑡 𝑝𝐻 7.4  
after 48 hours; stability was defined as released DOX% at pH 7.4 after 48 hours.   
CCD by 2 factors and 5 central points consisted of 13 runs with alpha level (α = 2k/4, k= 
number of factors) at 1.414 for two independent variables.  The ranges and level of the variables 
are listed in Table 4.1.  The complete CCD design matrix of experiments and the responses from 
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a total of 13 experiments were presented in the Table 4.6.  CCD and response surface diagram 
were constructed using Design-Expert (7.0.0) software. 
 
Table 4.1.  Factors and the correspondent values in coded and physical form 
Factors Code 
Levels 
-α -1 0 +1 +α 
AZE% X1 25% 28.66% 37.5% 46.34% 50% 




All runs in CCD experiments were prepared by ethanol injection methods listed in 
2.2.2.2.  The liposomes were characterized by the methods listed in 2.2.4 while doxorubicin 
concentration and drug encapsulation efficiency were determined by the methods listed in 2.2.5.  
pH-sensitivity and stability were evaluated by direct resin adsorption release assays listed in 
3.2.5.   
4.2.4 Prediction by RSM.  The optimal factor level as reflected by the AZE-C16 and 
cholesterol molar percentage in the composition was predicted by Design-Expert (7.0.0) software 
(Stat-Ease, Minneapolis, MN).  The criteria of independent factors and response were listed in 
















AZE% In range 10 60 1 1 - 
Chol% In range 20 40 1 1 - 
Size Minimize 100 300 1 - +++ 
PDI Minimize 0.1 1 1 - ++++ 
pH 
sensitivity 
Maximize 0 40 - 1 +++++ 
Stability Minimize 0 50 1 - ++++ 
Drug 
loading 




4.2.5 Data analysis.  Data are presented as mean ± standard deviation (SD) for the 
screening design study.  The statistical analysis was performed by t-test for the pegylated lipid 
composition study using GraphPad Prism 6.0 Software (GraphPad Software, La Jolla, CA).  
Model selection and analysis of variance (ANOVA) for select model were performed using 
Design-Expert 7.00 Software (Stat-Ease, Minneapolis, MN).  The results with p < 0.05 were 
accepted as statistically significant.  Response surface plot and contour plot was generated by 
Design-Expert (7.00) Software. 
4.3 Results and Discussion 
4.3.1 Effect of pegylated lipid composition.  The effect of pegylated lipid in the bilayer 
of liposomes on the size, PDI, drug loading and pH-sensitivity was evaluated with the select 
compositions listed in Table 4.3.  The fliposomes with two different pegylated lipids didn’t show 
much change on the size, PDI, drug loading capacity, as suggested in Table 4.3.  A slight 
increase of size was observed with the fliposomes prepared with PEG-ceramide, which is a 
potential reason for the small increase of drug loading.  Both fliposomes have similar PDI values 
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around 0.2, suggesting homogenous size distribution of the colloid system.  Apparently, 
significant difference in pH-sensitivity was observed between the two pegylated lipids.  In Figure 
4.1, the fliposome with PEG-ceramide released 16% more than the one with PEG-DPPE after 24 
hour incubation at 37°C.  This drastic increase could be contributed by the charge of pegylated 
lipid molecule.  PEG-Ceramide is neutral while PEG-DPPE is negatively charged.  When the 
fliposome was exposed to the environment of lower pH, those negative charged phosphate group 
in PEG-DPPE would compete with TACH lipid to grab proton.  Because there was 5% such 
molecules in the bilayer, the pH-sensitivity would be counterbalanced.  This observation was 
also explained by potential ionic interaction between the phosphate group of DSPE-PEG and the 
protonated amine group in TACH C12 lipid [102], which is thought to compete with the 
formation of an intramolecular hydrogen bond by the TACH lipid.  Therefore, PEG-ceramide 
was chosen over PEG-DPPE for further investigation of liposomes. 
 
Table 4.3.  Composition, size, PDI, EE and drug loading concentration of select DOX-loaded 









Mor-C16 : DPPC : PEG-DPPE 50 : 45 : 5 158.8 0.177 71.70 0.717 
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Figure 4.1.  Pegylated lipid effect on release profile of DOX-loaded fliposomes at pH 6.0, 37°C 




4.3.2 Effect of cholesterol.  The effect of cholesterol in the bilayer of liposomes on the 
size, PDI, drug loading and pH-sensitivity is evaluated with the select composition listed in 
Table 4.4.  The liposomes with and without cholesterol in composition were characterized and 
result was listed in Table 4.4.  Without cholesterol in the bilayer of liposomes, the size and PDI 
were larger than the liposomes with cholesterol.  In addition, it was prominent that the drug 
loading was higher after adding cholesterol into the bilayer for the non-pH sensitive liposomes.  
Cholesterol also increased the stability of the liposomes, as indicated by the lower release of non-
pH-sensitive liposomes at all pHs ranging from 6.0 to 7.4 (Figure 4.2).   
 
Table 4.4.  Composition, size, PDI, EE and drug concentration of DOX-loaded liposomes with 
and without cholesterol 





DPPC : PEG-DPPE 95 : 5 219.4 0.474 36.6 0.366 
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Figure 4.2.  Cholesterol effect on release profile of DOX-loaded liposomes (DPPC : PEG-
DPPE= 95 : 5, DPPC : Chol : PEG-DPPE = 70 : 25 : 5) at defined pHs, 37°C after 24 hours.  




It was reported that cholesterol can stabilize liposomal formulation when added into the 
bilayer structure [140, 141].  It was found that cholesterol controlled the fluidity of the liposome 
bilayer by occupying the cavities between the hydrocarbon chains of phospholipid, thereby 
inhibiting the free movement of those fatty acyl chains in the dispersed liquid crystalline phase 
[142].  In the gel phase, cholesterol can disturb the crystalline chain lattice in the bilayer, thereby 
increasing the permeability of the liposome [143].  Therefore, cholesterol would augment the 
liposome stability when the temperature is elevated above the transition temperature (T > Tm) 
and would enhance the drug retention during the high temperature of incubation.  However, the 
incorporation of cholesterol would also decrease the pH-sensitivity because the fliposomes are 
exposed to the physiological temperature around 37°C in vivo, which is below their transition 
temperature.  In addition, it has been reported that the higher ratio of  cholesterol to DPPC (0.8 ~ 
1.0) in the liposome bilayer will form an extraordinary lateral order, which is an extremely stable 
system without noticeable transition temperature [142]. 
With those prominent influences on the physicochemical properties and on the pH-
sensitivity, cholesterol was chosen as primary factor for the further optimization.   
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4.3.3 Effect of phospholipid.  The effect of phospholipid in the bilayer of liposomes on 
the size, PDI, release profile was evaluated with the select compositions listed in Table 4.5.  The 
liposomes that were prepared with DPPC didn’t show any significant difference with those with 
DSPC in the physicochemical properties, such as size and PDI, however, lower drug release, no 
matter within conventional liposomes or fliposomes, was observed in the presence of DSPC.   
 
Table 4.5.  Composition, size, PDI and release percentage of DOX-loaded liposomes with 
different phospholipids (n=3). 
Liposome Molar ratio Size (nm) PDI pH 
Release%  after 
12 hr 
DSPC : Chol :PEG-
Ceramide  
70:25:5 134.3 0.093 6.5 41.5±1.6 
DPPC : Chol :PEG-
Ceramide 
70:25:5 116.4 0.046 6.5 58.9±1.6 
DSPC : Mor-C16 : PEG-
Ceramide  
70:25:5 122.1 0.084 7.4 42.2+1.0 
DPPC : Mor-C16 : PEG-
Ceramide 




It was well acknowledged that the transition temperature (Tm) of a liposome system is 
mainly determined by the Tm of the component lipids.  Tm is defined as the temperature at which 
the lipid bilayer has a physical change from the ordered gel phase to the disordered liquid 
crystalline phase[144].  The hydrocarbon length of the lipid tail and saturation/unsaturation of 
the fatty acyl chains of the lipids are the two main factors that determine the Tm.  In Table 4.6, 
five different phospholipids with different Tm are listed.  It was also reported that an increase in 
length of the hydrocarbon chain (and therefore transition temperature) is directly correlated to 
stability[145].  Therefore, incorporating DSPC or DPPC into the liposome bilayer to balance the 
stability and pH-sensitivity is considered as a key factor for further optimization.    
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       Tm (°C) 
DLPC 12 0 -1 
DMPC 14 0 23 
DPPC 16 0 41 
DSPC 18 0 55 




4.3.4 Effect of flipids.  The effect of flipid in the bilayer of liposomes on the size, PDI 
and pH-sensitivity was evaluated with the select composition listed in Table 4.7 and 4.8.  
Increase in size and PDI was observed along with an increase of molar percentage of flipids in 
the fliposome composition (Table 4.7).  It was also accompanied by the drastic increase in the 
resistance during the extrusion.  The PDI value was above 0.3, suggesting that the colloidal 
system was not stable, and/or that a large aggregation was forming.  Together these phenomena 
indicated that TACH lipids were not compatible with the liposomal bilayer structure at high mole 
percentages.  This may be caused by the steric hindrance of the amine head group as well as the 
cyclohexanol ring (Figure.  4.3).  In addition, the close-to-zero surface charge of the liposomes 
may also contribute to the aggregation.  On the other hand, a flipid was introduced to render the 
saturated and PEGylated liposomes pH-sensitive.  It was apparent that the pH-sensitivity in this 
case, which is the difference between the release percentage at physiological pH 7.4 and tumor 
microenvironment pH 6.0, will be boosted with increasing flipid composition.  It is demonstrated 
by the comparison in Table 4.8 that doubling the molar percentage of MOR-C16 lead to nearly 
18% raise of the pH-triggered release.   
Given the different effects of the flipid as discussed above, it is crucial to optimize the 
molar percentage of flipid to balance between pH-sensitivity and good colloidal properties of the 
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liposome.  Therefore, mole percentage of flipid was selected as another primary variable for 
further optimization. 
 
Table 4.7.  Composition, size, PDI of empty fliposomes of different mole percentage of the 
Tach-lipid. 
Liposome Molar ratio size (nm) PDI 
DPPC : MOR-C16 :PEG-Ceramide 65:30:5 116.7 0.169 
DPPC : MOR-C16 :PEG-Ceramide 55:40:5 179.3 0.459 




Table 4.8.  Composition, size, PDI and release percentage of DOX-loaded fliposomes at different 
mole percentage of the TACH-lipid MOR (n=3). 
Liposome Molar ratio Size (nm) PDI pH sensitivity % 
Release % 
after 48 hr 
DPPC : MOR-C16 :PEG-
Ceramide 
70 : 25 : 5 108.4 0.109 15.9±1.2 64.0±4.4 
DPPC : MOR-C16 :PEG-
Ceramide 
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4.3.5 Optimization of liposome composition with response surface methodology 
(RSM).  Based on the RSM approach, the total number of runs was calculated as 2k + na + n0, 
where k is the number of independent factors, 2k represents the full factorial design points, na 
represents the axial points determined by α level, and n0 is the replicate number of center point.  
In this experiment, we had 2 factors, and 5 central points to give 13 total runs.   
A general equation for the relation of independent variable and response is:  
Y=b0＋b1X1+b2X2+b3X1X2+b4X12+b5X22.   
Where Y is the dependent variable; X1 and X2 are the independent variables; b0 is the 
intercept coefficient, which is the model constant; b1 and b2 are the estimated linear coefficients 
for the factor X1 and X2 respectively; b3 is interaction coefficient and b4 and b5 are quadratic 
coefficients.  The magnitude and the mathematical sign of coefficients suggested the degree of 
effect upon the dependent responses.  The complete CCD design matrix of experiments and the 





Table 4.9.  CCD of experiments for optimization of AZE-C16 based fliposome utilizing DX-7 
















1 37.50 32.50 178.1 0.279 28.05 34.63 1.42 
2 28.66 41.34 173.3 0.255 15.70 27.63 1.73 
3 37.50 45.00 283.2 0.515 8.43 48.87 1.51 
4 46.34 41.34 187.9 0.328 8.64 44.04 1.42 
5 37.50 32.50 258.5 0.606 7.53 46.27 1.47 
6 37.50 32.50 212 0.359 17.15 48.89 1.10 
7 37.50 32.50 163.5 0.198 24.33 44.20 1.60 
8 46.34 23.66 228.7 0.575 18.00 51.38 1.30 
9 37.50 20.00 158.8 0.173 10.73 43.40 1.85 
10 50.00 32.50 175.8 0.195 12.90 42.71 1.13 
11 37.50 32.50 166.6 0.316 21.68 48.07 1.26 
12 28.66 23.66 139.9 0.308 13.63 46.71 1.42 








b0 b1 b2 b3 b4 b5 
Size (nm)  -90.44 16.56 -7.77 -0.237 -0.090 0.293 
PDI - - - - - - 
pH sensitivity (%) -181.0 6.29 5.21 -0.037 -0.066 -0.061 
Stability (%) - - - - - - 







According to the ANOVA test of model on all five dependent variables, none of them 
statistically fit to a quadratic model.  Only size, pH-sensitivity and drug loading were suggested 
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by lack of fit tests to fit as a quadratic model, and the coefficients of general regression equations 
for the actual factors were listed in Table 4.10.  Although the fitting was not good to have 
regression, the effect of two primary factors on key properties of the AZE-C16-based fliposome 
was still able to be evaluated.   
4.3.5.1 Effect of AZE-C16 and cholesterol percentage on size.  In order to fully utilize 
the EPR effect, size is the critical parameter which need to be well controlled during the 
preparation procedure.  For the simplicity procedure, the extrusion of all fliposome in 13 runs 
were only conducted through 200 nm polycarbonate filters 5 times for the sake of the 
productivity.  Therefore, all the sizes of fliposomes wouldn’t be close to 100 nm.  For the 
optimization purpose, it was one factor to reflect good quality of a colloidal system.  It was 
apparent that the size increased along with the increase of AZE% and Chol%.  It could also be 
reflected by the trends in response surface plot (Figure 4.4) and quadratic equation: size = -90.44 
+ 16.56 * AZE% - 7.77 * Chol% - 0.237 * AZE% * Chol% - 0.090 * (AZE%)2 + 0.293* 
(Chol%)2.   
 
Figure 4.4.  Response surface plot (3D) (left) and contour plot (right) showing the effect of 
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4.3.5.2 Effect of AZE-C16 and cholesterol percentage on pH sensitivity.  Rendering pH-
sensitivity is our main approach to improve pegylated liposomes.  According to the 3D response 
surface plot (Figure 4.5), the pH-sensitivity increased with the increase of AZE% or Chol% to 
certain extent, then the pH-sensitivity gradually decreases.  It was reflected by larger values in 
the central concentric circle of the contour plot.  The quadratic equation was pH sensitivity = -
181.0 + 6.29 * AZE% + 5.21 * Chol% - 0.037 * AZE% * Chol% - 0.066 * (AZE%)2 - 0.061* 
(Chol%)2.  Mathematically, after AZE% and Chol% went over certain value, the negative effect 
from the quadratic parts of the equation would counterbalance the positive contribution from the 
linear parts. 
 
Figure 4.5.  Response surface plot (3D) (Left) and contour plot (Right) showing the effect of 




4.3.5.3 Effect of AZE-C16 and cholesterol percentage on drug loading.  Drug loading 
was an important response of RSM we would like to look into because of the needs of the animal 
studies.  Higher loading gave more flexibility to conduct animal experiments.  The market 
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to get close to 2 mg/ml at non-optimized condition.  Among three of the quadratic models, drug 
loading was least significant relative to the noise.  According to the equation from the modeling, 
Drug loading = 2.017+ 0.097 * AZE% - 0.148 * Chol% - 6.01E-4 * AZE% * Chol% - 1.10E-3 * 
(AZE%)2 + 2.61E-3 * (Chol%)2, where the intrinsic drug loading is close to 2 mg/ml at our 
current lipid to drug ratio (4:1, wt : wt).  The contribution from lipid composition was limited, 
while the drug-loading would decrease along with more cholesterol in the liposome bilayer 
(Figure 4.6).  It can be easily explained by the fact that cholesterol by itself is not conducive to 
the formation of the lipid bilayer, and thus would decrease the total number of liposome vehicles 
available for drug loading with the increase of its molar ratio.   
 
 
Figure 4.6.  Response surface plot (3D) (Left) and contour plot (Right) showing the effect of 




4.3.5.4 Prediction of AZE-C16 based fliposome by RSM optimization.  Based on the 
constraints of the criteria set up, 30 starting points were simulated by Design-Expert.  One 
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responses in target was obtained, of which the lipid composition is AZE: DSPC: Chol: PEG-
Ceramide = 38: 32: 25: 5.  The predict response is listed in Table 4.11. 
 
















Several factors in the preparation of liposome formulation were investigated.  The 
Neutral pegylated lipid, PEG-Ceramide was chosen for enhanced pH-sensitivity.  Cholesterol 
and DSPC were necessary for the stability of the liposomes, including the AZE-C16-based 
fliposomes of quick response.  RSM was utilized to further optimize the AZE-C16 based 
fliposome.  AZE: DSPC: Chol: PEG-Ceramide = 38: 32: 25: 5 was predicted by RSM to have 
relatively high stability and pH-sensitivity.  The optimized formulation was brought for further 
biological evaluation of efficacy together with another fliposome formulation MOR-C16: DPPC: 






Chapter 5: Evaluation of Anticancer Efficacy of Doxorubicin-loaded Fliposome in vitro  
 
5.1 Introduction 
The main stream strategy in the pharmaceutical industry to screen anticancer drugs and to 
validate their activities is to use two-dimensional models of cultured cells in vitro and animal 
models in vivo.  Although in vitro 2D monolayer cell culture has many advantages such as 
convenience, high throughput and low-cost, their main drawback is the lack of cell-cell and cell-
matrix interactions.  In addition, although solid tumors usually carry variations in oxygen level, 
metabolite concentration and acidic extracellular pH, such features are all missing in 2D cell 
culture models [147].  More and more studies have discovered the poor correlation between the 
monolayer cell models in vitro and the animal models in vivo, which would explain the gap 
between findings at early stages of drug screening and late stages of drug development.  
Therefore, there is a great demand of cost-efficient and accurate in vitro models to bridge such a 
gap, especially in oncology. 
3D MCS were established in the 1970s by Sutherland et al [148], and have now 
demonstrated many advantages over 2D cell culture models.  3D MCS are self-assembled under 
conditions that allow cells to grow and interact with their surroundings in three dimensions.  A 
necrotic core can be observed in MCS when the size reaches 500 µm.  The necrotic core is 
surrounded by a proliferative zone and a quiescent zone [149].  A typical configuration of 3D 
MCS (> 500 µm) with different areas is shown in Figure 5.1.  3D MCS include many features of 
solid tumors that are missing in 2D monolayer cells and thus have been proven to better mimic 









The difference between using 3D MCS and 2D cell culture was demonstrated by many 
researches [152, 153].  Colley et al. [154] reported that the delivery of drugs into the core of the 
3D MCS model of head and neck squamous cell carcinoma cells is crucial for the therapeutic 
effect while much lower exposure of the drug to the corresponding 2D monolayer cells 
substantially decreased the cancer cell viability.  In breast cancer treatment, Pickl et al. [152] 
reported that the HER2 activation is enhanced in 3D MCS because the HER2 homodimer could 
be formed in the model whereas only HER2/HER3 heterdimer, but not the HER2 homodimer 
could be formed on the surface of monolayer cells.  3D MCS can be formed by many different 
breast cancer cell lines, including TNBC[155-157].  Moreover, a pH gradient has been 
demonstrated in 3D MCS model, a feature of the tumor microenvironment that would greatly 
facilitate the characterization of the pH-sensitive fliposomes [158]. 
Therefore, 3D MCS can serve as a better platform for cancer research by providing a 
more physiologically relevant microsystem.  3D MCS of TNBC can evaluate the efficacy of 
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fliposomes as a better prediction of fliposomes’ anticancer activities in vivo.  The aim of this 
chapter’s studies is to construct and characterize TNBC 3D MCS and evaluate the anticancer 
efficacy on 3D MCS. 
5.2 Materials and Methods 
5.2.1 Materials.  MDA-MB-231 and MDA-MB-468 cell lines were purchased from 
ATCC (Manassas, VA, USA).   Advanced F12/DMEM, Non-Essential Amino Acid (NEAA), 
Collagen I, Bovine, Live/DEAD TM Cell Imaging Kit, Nigericin, Carboxy SNARF®-1, 
acetoxymethyl ester, acetate, and Trypsin-EDTA were purchased from Thermo-Fisher.  96-well 
Ultra-low Attachment Spheroid Microplates were purchased form Corning.  HEPES and MES 
were purchased from Fisher.  Tris was purchased from Sigma-Aldrich. 
5.2.2 Cell culture condition.  
5.2.2.1 Cell culture maintenance.  TNBC cell lines MDA-MB-231 and MDA-MB-468 
were maintained in Advanced F12/DMEM supplemented with 5% fetal bovine serum (Gemini, 
West Sacaramento, CA), 1% Penicillin-Streptomycin (Corning Life Science, Corning, NY) and 
1% L-glutamine (Invitrogen, San Diego, CA).  Cells were grown in 5% CO2 at 37 °C and 
passaged at 85% confluence.  (3~4 days).   
5.2.2.2 3D MCS formation.  MDA-MB-231 (~3000 cells/well), MDA-MB-468 (~2500 
cells/well) were seeded in the Corning ultra-low attachment 96 well plates with 1% collagen.   
The cells were centrifuged at 200 g for 15 minutes to facilitate the aggregation.  The growth 
media was changed every other day by replacing 100 μL of the media in the well with 100 μL 
fresh media to maintain a 200 μL total media volume.  The morphology of 3D MCS of each cell 
line was observed on an inverted microscope. 
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5.2.3 Live/dead cell assay.  The LIVE/DEAD Viability/Cytotoxicity kit from 
ThermoFisher was used to assess the viability of the cells inside 3D MCS according to 
manufacturer protocol.  Briefly, MDA-MB-468 cells (~2500 cells/well) were seeded in the 
Corning ultra-low attachment 96 well plate to form 3D MCS using the methods described above.  
At day 11-12 when the 3D MCS were at ~ 600 μm in diameter, three 3D MCS were transferred 
to a glass bottom dish containing 100 µL of total growth media for each cell line.  The 
LIVE/DEAD cell imaging kit reagent was added to the 3D MCS at equal volume per well.  The 
3D MCS were incubated for 45 mins at room temperature, washed 3 times with PBS and imaged 
using a Leica DMIRE2 confocal microscope.  The live cells give a green fluorescence signal at 
ex = 488 nm and em = 515 nm, while the dead cells give a nuclear read fluorescence signal at 
ex = 570 nm and em = 602 nm.  Images were acquired using the MetaMorph software and 
analyzed using the ImageJ software.    
5.2.4 pH gradient inside 3D MCS.  The emission spectrum of Carboxy SNARF-1 shifts 
along with the change of pH so Carboxy SNARF-1 can be used to measure the pH gradient 
inside 3D MCS.  Carboxy SNARF-1 is typically excited at one wave length between 488 nm and 
530 nm and simultaneously emits fluorescent signal at two wavelengths, typically at about 580 
nm and 640 nm.  The pH can be determined by the ratio of these two fluorescent signals.  MDA-
MB-468 cells (~2500 cells/well) were seeded in the Corning ultra-low attachment 96 well plate 
to form 3D MCS using the methods described above.  At day 11-12 when the 3D MCS were at ~ 
600 μm in diameter, three 3D MCS were transferred to a glass bottom dish containing 100 µL of 
total growth media.  SNARF-1 was dissolved in anhydrous DMSO at concentration of 100 μM 
and added to 3D MCS in the glass bottom dish to a final concentration of 10 μM.  The 3D MCS 
were then incubated for 45 mins at 37°C, washed 3 times with PBS and imaged using a Leica 
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DMIRE2 confocal microscopy.  At the end of an experiment, 3D MCS loaded with Carboxy 
SNARF-1 was exposed to three calibration solutions of 10 µM nigericin at pH 5.5, 6.8 and 8.0.  
The solutions were composed of 140 mM KCl, 1 mM MgCl2, 0.5 mM EGTA and 20 mM MES 
for pH 5.5, 20 mM Hepes for pH 6.8 or 20 mM Tris mM for pH 8.0.  Three calibration images at 
each pH were recorded in triplicate. 
 
Figure 5.2.  The emission Spectra of carboxy SNARF-1 indicates the correlation between pH and 




pH = p𝐾𝑎 − log [
𝑅−𝑅𝐵
𝑅𝐴−𝑅
 ×  
𝐹𝐵(𝜆2)
𝐹𝐴(𝜆2)
]                                                 (1) 
The pH at a given point in the fluorescent images can be estimated using the above 
equation, where the pKa of carboxy SNARF-1 is ~ 7.5, R is the ratio of the fluorescence 
intensities at the two wavelengths λ1= 580 nm and λ2= 640 nm (Fλ1/Fλ2).  Subscripts A and B 
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represent the limiting values at the acidic and basic endpoints, respectively.  From the equation 
we can see pH is directly correlated to the R value - the higher R is, the lower pH would be.  
However, the background signal needs to be subtracted before the calculation of R.  Images were 
acquired using MetaMorph software and analyzed using ImageJ software.  One z-stack picture at 
200 µm above the bottom of each 3D MCS was selected for the analyses and divided into five 
areas using concentric circles.  Each of the five areas was numbered 1 to 5 from the center to the 
edge.  The mean value of the two emission fluorescence signals of each region was measured.  
The R value of each region was then calculated after subtracting the background noise.  pH value 
was then calculated by the above equation.   
5.2.5 Cytotoxicity assays for DOX-loaded liposomes on 2D monolayer cells and on 
3D MCS.  MDA-MB-231 cells (~ 10,000 cells/well) and MDA-MB-468 cells (~ 5,000 
cells/well) within 15 passages were seeded into 96-well plates and incubated at 37 °C with 5% 
CO2 overnight.  The complete medium was then replaced, respectively, with 200 µL culture 
mediums containing DOX-loaded liposomes and free DOX at incremental concentrations.  After 
incubation for 72 hours, 20 µL CellTiter 96® AQueous One Solution cell proliferation assay 
(Promega Corp., WI, USA) was added to each well when 100 µL complete growth medium was 
replaced to stop treatment.  After further incubation at 37 °C with 5% CO2 for 4 h, the 
absorbance at 490 nm was recorded by Synergy HT microplate reader.  The cells that were 
exposed to only the growth media were assayed following the same procedure and taken as 
100% viability reference.  Samples were evaluated in quadruplicates.    
MDA-MB-231 cells (~ 3,000 cells/well) and MDA-MB-468 cells (~ 2,500 cells/well) 
within 15 passage were seeded into Corning ULA 96-well plate to form 3D MCS using the 
method described above.  After 11-13 days when the spheroids grew to ~600 µm in diameter, 3D 
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MCS were treated with free Dox and liposomal Dox at incremental concentrations in complete 
medium.  After incubation for 72 h at 37°C with 5% CO2, 3D MCS for each treatment group 
were transferred to an opaque-walled 96-well plate with 100 µl medium in each well.  An equal 
volume of CellTiter-Glo 3D cell viability assay (Promega Corp., WI, USA) was added to each 
well.  The plate was shaken for 5 minutes and incubated for an additional 20 minutes at room 
temperature to stabilize the luminescent signal.  The luminescence was then recorded by a 
Synergy HT microplate reader. The cells that were treated only with the growth media were 
assayed following the same procedure and taken as 100% viability reference.  Samples were 
evaluated in quadruplicates.    
5.2.6 Drug distribution in 3D MCS.  The distributions of free DOX and DOX-loaded 
liposomes within 3D MCS were determined by Laser confocal microscopy.  MDA-MB-231 and 
MDA-Mb-468 3D MCS with a diameter of about 600 µm were harvested 11~ 13 days after 
seeding.  All the 3D MCS were treated with 10 µg/ml free DOX or equivalent DOX-loaded 
liposomes and incubated at 37 °C with 5% CO2 for 4 hours.  The medium was then removed and 
MCS were washed with PBS.  The spheroids were transferred to a glass bottom dish and 
observed on a Leica DMIRE2 laser confocal microscope with the following setup: Exposure 
(1s), Gain (1x), Image Scaling (1000-7000) and z step (10 µm).  The excitation and emission 
were at 470 nm and 585 nm, respectively.  Images were acquired using MetaMorph software and 
analyzed using ImageJ software.  The semi-quantitative analysis of mean fluorescence intensity 
of free DOX, DOX-loaded liposomes in 3D MCS was made by calculating the mean 
fluorescence intensity of each multicellular spheroids.  All pixels’ fluorescence intensity of 
regions of interest were counted and normalized by the area.   
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5.2.7 Data analysis.  Data are presented as mean ± standard deviation (SD) for the all 
cytotoxicity assay study.  IC50 was generated by nonlinear regression, log(inhibitor) vs. viability.   
Response model using GraphPad Prism 6.0 Software (GraphPad Software, La Jolla, CA).  The 
statistical analysis was performed by one-way analysis of variance (ANOVA) for IC50 
comparison using GraphPad Prism 6.0 Software.  Tukey’s post hoc test analysis was performed 
to compare between the treatment groups.  The results with p < 0.05 were accepted as 
statistically significant.    
5.3 Results and Discussion 
5.3.1 Formation of 3D MCS.  Relatively tight multi-cellular spheroids of two TNBC cell 
lines were successfully constructed at select seeding density after the application of 
centrifugation and the use of collagen in the seeding media.  As mentioned before, spheroids 
with diameters larger than 500 µm commonly have a necrotic core surrounded by a viable layer 
of quiescent zone and an outer shell of proliferating cells[160, 161].  The gradients of 
metabolites, oxygen, nutrients and pH inside the 3D MCS make them a more physiologically 
relevant platform for testing drug delivery systems than 2D cell models.  The size of 3D MCS 
gradually increased within 15 days and MDA-MB-231 formed tighter structure than MDA-MB-
468, shown in Figure 5.3.  The growth curve of 3D MCS of MDA-MB-231 was validated with 





Figure 5.3.  Morphology of MDA-MB-231 (3000 cells/well, upper) and MDA-MB-468 cells 





Figure 5.4.  Growth Curve by size and 3D cell viability assay with MDA-MB-231 (3000 




5.3.2 Distribution of live and dead cells inside 3D MCS.  Figure 5.5 shows the image 
of a 100 m-deep cross section near the core of 3D MCS of MDA-MB-231 and MDA-MB-468 
cells.  The green signal from the fluorophore Calcein-AM represent the live cells while the red 
signals from the fluorophore ethidium homodimer-1 represent the dead cells.  The confocal 
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images of both cell lines show that the green signals are concentrated in the peripheral areas, 
indicating a proliferation zone while the red signals distribute mainly in the core, indicating a 
necrotic zone.  This phenomenon was also demonstrated by the semi- quantitative accumulation 
of relative florescent signal at two wavelengths.   
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Figure 5.5.  Confocal Image of the distribution of live and dead Cells in MDA-MB-231 (upper 
left) and MDA-MB-468 (lower left) 3D MCS.  Live cells fluoresce green, dead cells fluoresce 
red.  The fluorescence intensity profiles (right) for both channels show the different distribution 




5.3.3 pH gradient in 3D MCS.  Based on the equation (1) listed in section 5.2.4, the R 
value is inversely proportional to the pH value.  For an identified sample, RA, RB, FA(λ2) and 
97 
 
FB(λ2) are constant, which means the pH is a function of a single variable R.  The descending 
trend was observed from the central area to the peripheral area of the concentric circles (Area 1 
to Area 5).   At the limiting acidic and basic conditions, RA, RB, FA(λ2) and FB(λ2) were selected 
from the area closer to the edge of the same z-stack, which was equilibrated to the calibration pH 
by the K+/H+ ionophore nigericin[162].  The intra-MCS pH decreased along the radius from the 
edge to the core, which was listed in Table 5.1.  Although the calculated pH value was greatly 
impacted by the morphology and tightness of 3D MCS, the descending trend of pH inside 3D 
MCS was validated.  Therefore, 3D MCS is an excellent model to evaluate the efficacy of DOX-
loaded, pH-sensitive fliposomes in vitro. 
 
 
Figure 5.6.  Confocal Images of MDA-MB-468 3D MCS with SNARF-1 at two channels (green: 




Table 5.1.  R value and calculated pH inside 3D MCS of MDA-MB-468 
Area 1 2 3 4 5 
R 0.47 0.45 0.32 0.25 0.27 




5.3.4 Cytotoxicity assay for DOX-loaded liposomes on 2D monolayer cells and on 3D 
MCS.   
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Figure 5.7.  Viability of MDA-MB-231 monolayer cells (left) and MDA-MB-231 3D MCS 




Table 5.2.  IC50 of Different Dox Formulations on 2D monolayer and 3D MCS of MDA-MB-





































The fifty percent inhibitory concentration (IC50) value of each DOX or DOX-loaded 
liposome formulation was calculated from data shown in Figure 5.7 using the GraphPad Prism 
software.  Against 2D monolayer of MDA-MB-231 cells, free DOX, DOX-loaded non pH-
sensitive liposome and fliposomes had similar IC50 values, where no statistically significant 
difference was found among free DOX, non pH-senstivie liposome and MOR-C16 fliposome 
groups.  There was the same trend of IC50 values observed against 3D MCS of MDA-MB-231 
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cells.  IC50 value of each treatment group didn’t show statistical difference among all treatment 
groups due to the large standard deviations.  Based on IC50 value, ranking of anticancer efficacy 
against 3D MCS was listed as free DOX > MOR-C16 fliposome > stealth liposome > AZE-C16 
fliposome, as shown in Table 5.2. 
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Figure 5.8.  Viability of MDA-MB-468 monolayer cells (left) and MDA-MB-468 3D MCS 




Table 5.3.  IC50 of Different Dox Formulations on 2D monolayer and 3D MCS of MDA-MB-
468 cells after 72 h exposure.  Data presented as mean ± SD, N = 4. 











2D 0.045 ± 0.012 0.095 ± 0.031 0.083 ± 0.017 0.153 ± 0.056 




The anticancer activities against MDA-MB-468 cells gave a completely different profile.  
IC50 value of free DOX was lower than any other treatment groups on 2D model.  MOR-C16 
Fliposome shared similar anticancer efficacy with conventional liposome, but only free DOX 
and MOR-C16 Fliposome were significantly better than AZE-C16 Fliposome (p<0.05).  To 
compare IC50 values of different formulations of DOX against 3D MCS of MDA-MB-468 cells, 
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there was no statistically significant difference among the groups of free DOX, conventional 
liposome, MOR-C16 fliposome and AZE-C16 fliposome. 
Comparing to evaluation anticancer efficacy by change of size and morphology [163-
165], evaluation by IC50 against 3D MCS is more convenient and accurate.  Generally, IC50 value 
of any treatment group against 3D MCS was much greater than the IC50 value against 2D 
monolayer cells.  This could be explained by the fact that penetration resistance was much higher 
in the 3D MCS model, which reflected a much more realistic environment of tumor.  However, 
different TNBC cell lines exhibited different degree of the increase of the IC50.  This 
phenomenon could be explained by the different tightness of the MCS of different cell lines, 
which affect the drug penetration and thus the drug activity.  All of the results suggest that, after 
long time exposure, the cytotoxicity was enhanced in 3D MCS but not in monolayer cancer cells.  
This could be attributed to the enhanced release of DOX from the fliposomes, especially the 
MOR-C16 fliposome, in the acidic environment inside 3D MCS.   
5.3.5 Drug distribution inside 3D MCS.  The selected formulation demonstrated 
different levels of anticancer activity on the TNBC in vitro model between 2D monolayer cell 
and 3D MCS.  The difference is caused by many factors, of which one potential factor is the drug 
penetration resistant in 3D MCS model.  Full exposure of drug to 2D model enables the quick 
equilibrium and complete cytotoxic effect, which is not seem in the 3D MCS as well as solid 
tumor.  The fluorescent signal of doxorubicin distributed inside 3D MCS gave us insight on how 





Figure 5.9.  Confocal Images of MDA-MB-231 3D MCS (cross section at 120 µm deep) Treated 
with Free Dox (A), Dox-loaded Non pH-sensitive liposome (B) and Dox-loaded MOR-C16 




After a 4 h incubation with different treatment groups of equivalent amount of DOX, 
confocal microscopy images of cross sections of MDA-MB-231 3D MCS at about 120 µm from 
the bottom were taken and the fluorescent signal of DOX was analyzed (Figure 5.9).  Stronger 
fluorescent signals of MCS that were treated with liposomal DOX were observed in comparison 
to those treated with Free DOX.  An intense ring of DOX accumulated was observed in the outer 
proliferative cells of each 3D MCS, indicating limited penetration of all formulations into MCS 







Figure 5.10.  Confocal Images of MDA-MB-468 3D MCS (cross section at 120 µm deepth) 
treated with Free DOX (A), DOX-loaded conventional liposome (B), DOX-loaded MOR-C16 




No qualitive difference of fluorescent intensity was observed among groups of MDA-
MB-468 3D MCS after treatment by free or liposomal DOX for 4 h except for AZE-C16 
Fliposome (Figure 5.10).  This result suggests that both free DOX and DOX-loaded liposomes 
could penetrate into MDA-MB-468 3D MCS with similar efficiency given 4 h of exposure time. 
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When the penetration of DOX into 3D MCS of two TNBC cell lines was compared with 
the penetration of liposomal DOX (4 hour of exposure time), the liposomal DOX groups showed 
more penetration than the free DOX in 3D MCS of MDA-MB-231 cell lines, but no qualitive 
difference of penetration into 3D MCS of MDA-MB-468 was observed between liposomal DOX 
and free DOX.  This phenomenon indicated the association between the cell line that formed the 
3D MCS and the DOX penetration into the 3D MCS, which was consistent with the report by 
Namhuk, et al. [163].  Cellular accumulation and uptake of a weakly-basic drug, such as 
doxorubicin has been reported to decrease along with lower extracellular pH [166-168].  At low 
pH in the MCS interstitium, such as area 2 in Figure 5.6, the ionized DOX has low lipid 
solubility and high electrical resistance, thus a greatly reduced membrane penetration.  If one cell 
line could form tight spheroid, such as MDA-MB-231, the diffusion of free DOX would be 
limited by such resistance.  However, if the cell line could only form loose aggregate, such as 
MDA-MB-468, the penetration wouldn’t be the limiting step for the cytotoxic effect of the 
anticancer agent.  Therefore, the enhanced cytotoxicity of the DOX-loaded fliposomes in 
comparison to conventional liposome, both of which has similar size and surface charge, could 
be attributed to the enhanced release of the fliposomes in response to the reduced pH inside the 
3D MCS, rather than differences in liposomal drug distribution. 
The confocal scanning of 3D MCS was performed with z-stack sectioning of 10 µm per 
step from the bottom to top.  The 100 µm depth was chosen due to the limit of the confocal laser 
scanning technique [169].  The degree of light penetration is greatly affected and reduced by the 
scattering in the sample and the defocusing of the illumination beam when the light travels over 
100 µm through sample [170, 171].  Therefore, the fluorescent signal at 100 µm depth from 
bottom was acceptable for comparison across different MCS without impact of light penetration 
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issues.  Multiphoton microscopy can be utilized in the future studies since the excitation photon 
would be split into multi photons which carry the same energy as a sum but have much longer 
wavelength for deeper penetratioin [172].  Still this technique can only enhance the penetration 
of the excitation photons, but not the emission photons.  Cryosection is another alternative way 
to address the light penetration issue by cutting the spheroids into sections of 10 – 20 µm in 
thickness.  High resolution images of each section can then be easily obtained using confocal 
microscopy [173].  The drug distribution in the cryosections could also be directly measured by 
MALDI Imaging Mass Spectrometry [174].     
5.4 Summary 
3D MCS of TNBC was successfully established for in vitro efficacy evaluation.  Cell 
viability and pH gradient inside 3D MCS were validated to confirm that MCS possess the 
essential microenvironment as an appropriate model to evaluate pH-sensitive liposomes.  Free 
DOX, DOX-loaded conventional liposome and DOX-loaded Fliposome were evaluated in 3D 
MCS model.  DOX-loaded Fliposome, especially the MOR-C16 fliposome (DPPC : Mor-C16 : 
PEG-Ceramide = 70 : 25 : 5), showed improved efficacy than the conventional liposome (DPPC 
: Chol : PEG-Ceramide = 70 : 25 : 5) based on IC50 value.      
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Chapter 6: Evaluation of Anticancer Efficacy of Doxorubicin-loaded Fliposome in Mice 
 
6.1 Introduction 
Animal models are still the most important evaluation tools to bridge the gap between the 
discovery of drug candidates in vitro and their clinical development.  Although many innovative 
techniques and mechanistic studies have emerged to allow better prediction of a drug candidate’s 
efficacy and safety from its data in vitro, animal models, especially mice models in oncology are 
still essential in evaluating a drug candidate before any further trial in human [175].  The animal 
models in oncology are typically utilized to simulate a cancer’s invasion, metastasis and 
therapeutic response to the new drug candidate.  Therefore, robust and relevant animal models 
are paramount to test our hypothesis after tremendous work in formulation and in vitro 
evaluation. 
Human tumor xenograft models in nude mice stand out from various animal models 
because of the low cost, ease to handle and numerous support information [176].  Since the first 
mouse leukemia models grown as ascites back to 1960, tremendous effort has been devoted to 
build various tumor models in mice by millions of scientists [177].  For breast cancer, the 
xenograft models was successfully established in 1969 [178] and the orthotopic metastatic breast 
cancer was established by transplanting a patient-derived xenograft fragment into the nude 
mouse fat pad in 1993 [179].  Generally, there are different types of in vivo mouse model of 
breast cancer, including cell-derived xenografts (CDX), patient-derived xenografts (PDX) and 
genetically engineered mouse models (GEMM) [175].  It is widely accepted that the xenograft 
models are inferior to the GEMM due to immunodeficiency, but CDX is widely accepted for 
evaluating the response of human tumor to the therapy because PDX is severely limited by the 
resource [180].  Among the CDX of breast cancer, the ectopic CDX model which implants 
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human tumor cells subcutaneously into the immunocompromised mouse is most commonly used 
because it is fast, cheap and technically simple but still involves human breast cancer cells.  
However, this subcutaneous model does not appropriately reflect the reality of breast cancer.  In 
particular, the perfusion of blood in such subcutaneous tumor is more than the tumor in situ, 
which exaggerates the EPR effect.  In contrast, an orthotopic CDX model of breast cancer 
implants human breast cancer cells in the murine mammary gland/fat pad, which would provide 
the xenograft a microenvironment similar to that of breast cancer while the xenograft tumor size 
is still measurable with calipers.  In addition, sex hormone levels play a critical role in the 
tumorigenesis of TNBC, which makes the orthtopic TNBC xenograft mice model an excellent 
system to evaluate the efficacy of fliposome.  Nevertheless, it must be noted that the 
immunodeficient mouse model of orthotopic implantation doesn’t perfectly reproduce the 
tumorigenesis in human because the host immune cells at the tumor site would also play 
important roles in the genesis, progression and metastasis of a TNBC tumor [181]. 
Generally regression of tumor and longer survival is utilized in clinical studies to indicate 
the efficacy of the therapy.  Some studies failed to achieve observable tumor regression because 
the administration of sub therapeutic doses, in which less cytotoxicity can prolong the duration 
of study.  Overall tumor volumes were calculated and compared to non-treatment or reference 
treatment to assess efficacy.  The timing of dosing the drug candidate is a key parameter that 
affects the outcome of such an experiment.  A “tumor growth delay study” is more reliable for 
assessing the potential of a treatment because the first dose is initiated after the appearance of the 
solid tumor rather than before the appearance of a small solid tumor, which is known as “tumor 
growth inhibition study”.   
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Preparation of doxorubicin in a liposomal formulation can change the pharmacokinetics 
and pharmacodynamics of the drug to achieve lower toxicity and higher efficacy of the therapy 
[38].  Hence, information on the pharmacokinetics of fliposome will help us better understand 
the correlation between its in vitro feature and in vivo efficacy and safety.  The aim of this 
Chapter’s studies is to determine the efficacy of the DOX-loaded pH-sensitive fliposome as 
compared to conventional liposomes against TNBC on the orthotopic xenograft mouse model. 
6.2 Materials and Methods 
6.2.1 Materials. 
6.2.1.1 Chemical agents.  Isoflurone, ketamine, xylazine, and heparin were purchased 
from Patterson Veterinary (Saint Paul, MN).  High-performance liquid chromatography (HPLC)-
grade acetonitrile, and acetic acid were purchased from Fisher Scientific (Fair Lawn, NJ). 
6.2.1.2 Animals.  For the pilot pharmacokinetic study, jugular vein-cannulated female 
athymic nude mice (NU- Foxn 1nu) were obtained from Charles River at 8 weeks of age; for 
anticancer efficacy evaluation, female athymic nude mice (NU- Foxn 1nu) were obtained from 
Charles River at 5 weeks of age.  The in vivo study was performed based on the animal protocol 
(No. 16R0r) which was approved by the Institutional Animal Care and Use Committee 
(IACUC), University of the Pacific.  The mice were housed in a temperature-controlled room 
with a 12-hour day/night lighting cycle and were housed individually if cannulated.  All mice 
were fed standard murine chow and water ad libitum. 
6.2.2 Pilot pharmacokinetic study.  
6.2.2.1 Pilot pharmacokinetic study design.  The DOX-loaded AZE-C16 fliposome 
listed in the 4.3.5 (5 mg/kg equivalent doxorubicin) was administered via jugular vein cannula to 
female mice.  Blood samples (100 µL) were gently withdrawn from the jugular vein cannula 
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followed by fluid replacement (equivalent volume) with sterile saline at each time point.  The 
assignment of mice sampled, and the time point was shown in Table 6.1.  The total blood volume 
withdrawn (excluding terminal samples) was no greater than 10% of the animal’s total blood 
volume within first 24 hours.  At terminal time point (48 or 72 hour), animals were anesthetized 
(isoflurane: 2-3% induction and 1-2% maintenance) and blood sample was taken by cardiac 
puncture.  All blood samples were mixed with sterilized water at volume ratio 1:2 in order to lyse 
all blood cells.  The samples were then stored at -20℃ until further analysis. 
 
Table 6.1.  Sequential assignment of sampling in pilot pharmacokinetic study (six mice coded by 
letter A through F)  
Time(hr) 1 2 8 24 48 72 
Mice to be sampled A A D E A B 
D B B F C D 




6.2.2.2 Sample preparation.  DOX (1000 µg/mL) and Daunorubicin (1000 µg/mL) were 
prepared in methanol and stored at -20 °C.  The solutions of DOX were further diluted with 
methanol to give a series of standard solutions at 0, 1, 2, 20, 100, 200, 1000 μg/ml DOX 
concentrations.  Then 2.5 μl standard solutions were added into 47.5 μl lyzed blood to obtain the 
standard whole blood working solutions with at 0, 0.1, 1, 5, 10, 50 μg/ml DOX concentrations.  
Whole blood working solutions for quality control (QC) were prepared separately at 0.1, 5 and 
50 μg/ml DOX for low QC, moderate QC and high QC, respectively.  For standards and quality 
controls, 2.5 μl of Daunorubicin (100 μg/ml) was added into 150 μl of water-lysed standard 
whole blood working solution or QC solution.  For each unknown lysed whole blood sample, 2.5 
μl of Daunorubicin (100 μg/ml) was added to 150 μl lysed blood water mixture sample.  850 μl 
of acetonitrile with 1% formic acid was added to all samples and standards to precipitate plasma 
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proteins.  The DOX was de-chelated from Copper by sonication at 55°C for 25 minutes followed 
by centrifugation at 10000 rpm for 20 minutes at 4°C.  10 μl of the supernatant was aliquoted for 
analysis.   
6.2.2.3 LC/MS/MS assay.  The LC/MS/MS system included an Agilent 1100 series 
HPLC consisting of an online degasser, a binary pump, and an auto-sampler (Agilent 
Technologies, Santa Clara, CA) and an MDS Sciex API 3000 triple – quadruple tandem mass 
spectrometer equipped with a turbo ion spray (Applied Biosystems, Foster City, CA).  10 μl of 
sample was injected into a PLRP-S C18 column (150 × 2.1 mm i.d., 3-μm particle size; Varian 
Palo Alto, CA) with a ZORBAX RELIANCE C18 Guard column (12.5 × 4.6 mm i.d., 5-μm 
particle size; Agilent, Santa Clara, CA).  Mobile phase A was 0.1% formic acid in double-
distilled water.  Mobile phase B was 0.1% formic in acetonitrile.  A gradient elution with a flow 
rate of 250 μl/min was used to separate the compounds (Table 6.2).  The total running time is 15 
minutes.  The mass spectrometer was operated in positive ionization mode with multiple reaction 
monitoring.  Table 6.3 shows the detail of the mass spectrometer parameters of Doxorubicin and 
Daunorubicin. 
 
Table 6.2.  Gradient elution program 
Time (min) 0 4 4.03 5.3 6 15 
A% 80 50 5 5 80 20 







Table 6.3.  Mass spectrometer parameters for MRM of Doxorubicin 
Parameter (units) Doxorubicin Daunorubicin 
Q1/Q3 544.2/397.2 528.3/363.2 
Declustering potentials (volts 11 16 
Focusing Potential (volts) 70 120 
Collision Enegery (volts) 15 33 




6.2.2.4 Data analysis.  Data are presented as mean ± standard deviation (SD) for the 
pharmacokinetic study.  Non-compartmental analysis of the whole blood concentration time 
profiles was conducted in Phoenix WinNonLin to obtain AUCinf, Lambda_z and total clearance 
(CL).  Subsequently, the elimination half-life was calculated with the formula: t1/2 = 
ln2/Lambda_z. 
6.2.3 Anticancer efficacy evaluation on a TNBC orthotopic model. 
6.2.3.1 Establishment of TNBC orthotopic xenograft model.  The MDA-MB-468 cells 
were cultured and maintained in the Advance DMEM/F12 medium as described previously.  On 
the day of the experiment, the cells were trypsinized and re-suspended in medium followed by 
centrifugation at 200 g for 5 minutes.  After aspiration of the supernatant, the cell pellet was 
washed twice with PBS.  A cell counting by a Scepter™ 2.0 Handheld Automated Cell Counter 
(MilliporeSigma, Burlington, MA) was performed with the re-suspended cells in sterile PBS.  
Lastly the cells were re-suspended in the cold HBSS/Matrigel® Matrix (vol : vol = 1:1) mixture 
containing 0.04% Dnase, of which the cell density is approximately 8×108 cells/ml.  The cells 
suspension was maintained on ice until injection. 
For the ease of performing the orthotopic injection of tumor cells, the mice were 
anaesthesized (isoflurane: 2-3% induction and 1-2% maintenance).  The MDA-MB-468 cells 
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(8,000,000 cells/ mouse) were injected into the mammalian fat pad using a 27 gauge needle on 
the second nipple around the left axillary region of mice.  Following inoculation, the mice were 
observed daily for their general health and appearance of tumors.   
6.2.3.2 Study design.  The tumors were allowed to grow up to 70 - 100 mm3 for 2 weeks 
after inoculation.  The tumor bearing mice were randomly divided into five groups (control, 
doxorubicin solution, conventional liposome, MOR-C16 fliposome and AZE-C16 fliposome) 
with eight mice per group except for the control group (N=5).  Stratified randomization was 
based on size of tumor.  Afterwards, 5 mg/kg free doxorubicin, conventional liposome (5 mg/kg 
equivalent doxorubicin) and fliposomes (5 mg/kg equivalent doxorubicin) were diluted in 
sterilized PBS and administered to the mice once a week for 4 weeks, while PBS (100 μL) was 
administered as a control to evaluate the effect of no treatment.  The animals were anesthetized 
with isoflurane and the formulations were injected through tail vein.  Body weight was recorded 
and monitored to evaluate the safety; tumor size (in mm3) was measured with calipers every 
other day, and the tumor volume was calculated using the formula:  
𝑇𝑢𝑚𝑜𝑟 𝑣𝑜𝑙𝑢𝑚𝑒 (𝑚𝑚3) =  
1
2
× 𝐿 × 𝑆2 
where L the long axis and S is the short axis of the tumor lump.  The tumor and hearts 
were removed and weighted when the animals were euthanized by anesthetics overdose after 63 
days post first dosing.   
6.2.3.3 Data analysis.  Data are presented as mean ± standard error of mean (SEM) for 
the anticancer efficacy study due to large deviation of tumor volume based on measurement.  
The statistical analysis was performed by two-way analysis of variance (ANOVA) for the 
antitumor efficacy study using GraphPad Prism 6.0 Software (GraphPad Software, La Jolla, CA).  
Tukey’s post hoc test analysis was performed to compare between the treatment groups.  The 
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correlation analysis was performed for comparing the tumor volume measurement and the tumor 
weight. The results with p < 0.05 were accepted as statistically significant.    
6.3 Results and Discussion 
6.3.1 Doxorubicin LC-MS/MS assay.  The retention time for Doxorubicin and 
Daunorubicin was 6.65 and 7.18 minutes respectively.  The standard curve in blood is from 0.1 
to 50 μg/ml Doxorubicin (Figure 6.1) based on weighted regression (1/y) analysis (r2 >0.99) of 
the peak area ratio (Doxorubicin/Daunorubicin) versus Doxorubicin concentration.  LOD and 
LOQ is 0.01 and 0.1 µg/ml, respectively. 
 





6.3.2 Pilot pharmacokinetic analysis.  Figure 6.2 shows the average Doxorubicin 
concentration in blood of 6 mice (n =3/ timepoint) versus time after 5 mg/kg IV administration.  
Due to the low sensitivity of analysis assay, the concentration of the last three time points fell 
below the LOQ but above LOD, therefore the point of 24 hour was presented as the LOQ and 48 
and 72 hours were not used for analysis. The concentration of DOX in blood dropped quickly to 
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lower than 0.3 µg/ml (the IC50 value on 3D MCS) within 12 hours.  The pharmacokinetic curve 
showed the feature of two-compartmental model, which was not consistent with the reported 
three-compartmental model in the literature [182].  The values of area under the plasma 
concentration-time curve (AUC) and total clearance were in between of the values of pegylated 
liposome and free doxorubicin reported in the literature [183].  Elimination half-life calculated 
from the 8- and 24-h values was approximately 6.5 h, which was close to the value of free dox 
[184].  Comparing to the data listed in the literature [182-184], the pharmacokinetic profile of 
AZE-C16 fliposome was more similar with free doxorubicin other than pegylated liposomal 
doxorubicin, suggesting doxorubicin may leak prematurely from AZE-C16 fliposome during 
circulation before accumulation at the tumor site. 
 
Figure 6.2.  Doxorubicin blood concentrations following intravenous administration of DOX-
loaded AZE-C16 fliposome (5 mg/kg equivalent doxorubicin) to female nude mice.  Data 







6.3.3 Anticancer efficacy of pH-sensitive liposomes on TNBC orthotopic model.  The 
anticancer activity of fliposome was investigated using the above-mentioned orthotopic MDA-
MB-468 xenografts nude mouse model.  The treatment was started at a mean tumor size of 75 
mm3, and no tumor regression was observed.  Figure 6.3 shows the effect of different 
formulations on tumor volumes measured every other day for nine weeks.  The statistical 
analysis was performed using two-way ANOVA with data up to 61 days post first dose, after 
which the deviation within each group was getting larger.  Turkey post test comparisons between 
treatment groups showed that tumor volume of MOR-C16 treatment group was significantly (p < 
0.05) smaller than the one of free DOX treatment group from day 57 to 61, and significantly (p < 
0.05) smaller than the one of conventional liposome group at day 61.  There was a clear trend 
that the tumor progression of fliposome (MOR-C16 and AZE-C16) treatment groups was 
delayed compared to free DOX and conventional treatment group, which suggested the pH-
sensitive liposome did improve the anticancer activity against TNBC in an orthotopic xenograft 
model.  In addition, the tumor weight was correlated with the tumor volume at the end of the 
experiment, confirming that the tumor volume measurement accurately reflected the tumor 
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Figure 6.3. Anticancer efficacy of DOX formulations in mouse orthotopic xenografts bearing 
MDA-MB-468 breast cancer.  MDA-MB-468 cells were inoculated into the mammalian fat pad 
in the axillary of femal athymic nude mice.  The animals received ~100 µL of normal saline as 
control or 5 mg/kg of DOX in PBS or 5 mg/kg of equivalent DOX-loaded liposome on 0, 7, 14, 
21 days (indicated by arrows).  The data represent mean ± SEM of results calculated from 5 or 8 
animals.  * Significant difference (p<0.05 for two-way ANOVA) observed between MOR-C16 
and Free DOX group, # Significant difference (p<0.05 for two-way ANOVA) observed between 




Figure 6.4.  Correlation analysis of tumor weight and tumor volume at the end of experiment on 




Although there was statistically significant difference shown in limited days between the 
fliposome groups and the other groups, a benefit of pH-triggered release as a passive targeting 
strategy was still observed.  There are several areas that could be improved for future 
investigations.  First, the orthotopic breast cancer model could be improved by injecting TNBC 
cell at exponential phase under more robust conditions, which will facilitate tumor progression 
so that the tumor volume will have more apparent difference between different groups, which 
would provide better chance to observe statistically significant differences.  3D MCS of breast 
cancer cells could also be inoculated into the mammalian fat pad instead of the suspended cancer 
cells to form a more uniform size of tumor, which will reduce the deviation within each group.  
Secondary, another TNBC cell line could be chosen for further animal studies.  According to our 
cell culture studies, the liposomal doxorubicin will be more advantageous in the anticancer 
activities when the cell line could form tighter spheroids rather than loose aggregates in culture.  
The fold of increase of the IC50 value from 2D monolayer to 3D MCS would be a good indicator 
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to construct animal models that bears tighter solid tumors.  Thirdly, the therapeutic benefits of 
pH-triggered release against solid tumors rely first on the intratumoral accumulation of the 
formulation by the EPR effect.  Therefore, sufficient duration of circulation in blood, which is a 
key indicator of liposome stability in vivo is a major concern for the design of triggerable 
liposomes.  It was reported that 24 hour circulation is required for the manifestation of the EPR 
effect[138], and the total amount of DOX eventually displaying a therapeutic effect at tumor site 
would determine the utmost contribution by triggered release.  According to the pilot 
pharmacokinetic study, the AZE-C16 fliposome, which has better and quicker response upon 
lower pH , was less stable in the blood circulation than the reported conventional liposomes 
[184].  The less efficacy obtained of AZE-C16 fliosome compared to MOR-C16 could be 
explained by unexpected premature leakage during the blood circulation, leading to the quick 
dropping of drug concentration in blood within 8 hours and the insufficient intratumoral 
accumulation through the EPR effect.  As an improvement, the optimization of formulation 
should highlight stability as a priority, especially stability at 24 hours to provide a fundament for 
sufficient circulation of the delivery system under study. 
6.3.4 Cardiotoxicity evaluation.  During the whole experiment, no mice showed drastic 
decrease of the body weight.  It is also reported that heart weight to body weight ratio would 
decrease when doxorubicin accumulated excessively into the heart [185, 186].  In this study, the 
heart weight to body weight ratio among all treatment groups had no significant difference 
compared to the non-treatment group (Figure 6.5).  All the animals possessed steady body 
weight.  It was reported that the median cumulative cardiotoxic dose of doxorubicin was 36.4 
mg/kg found in the mouse [187], which was much higher than our experiment design.  In order 
to get better tumor regression efficacy, higher dosage of liposomal doxorubicin could be used in 
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future research.  Lastly, the administration of free DOX induces the accumulation of reactive 
oxygen species in heart.  Therefore, cardiotoxicity would be another safety issue that warrants 


























































































Figure 6.5.  Effect of doxorubicin and liposomal DOX on the heart weight to body weight ratio 
as an indicator of doxorubicin-induced cardiotoxicity in nude mice on Day 63 after the first IV 
injection.  The data represent mean ± SD of results calculated from 8 animals (Saline group 
N=5).  One-way ANOVA followed by Tukey's multiple comparison test suggested no significant 







 An orthotopic TNBC xenograft mice model was successfully established for in vivo 
efficacy evaluation.  Anticancer activity of free DOX, DOX-loaded conventional liposome and 
DOX-loaded Fliposome was evaluated in the orthotopic xenograft model by monitoring the 
tumor progression for 61 days.  DOX-loaded Fliposome, especially the MOR-C16 fliposome 
(DPPC : Mor-C16 : PEG-Ceramide = 70 : 25 : 5), showed improved efficacy than the 
conventional liposome (DPPC : Chol : PEG-Ceramide = 55 : 40 : 5) which was suggested by the 
delay of the tumor progression.  The AZE-C16 fliposome was less effective than the MOR-C16 
fliposome probably due to its lower stability, which was observed in its  in vitro release profile 
and in the pilot pharmacokinetic study.  The quick response of AZE flipids to lower pH, also 
suggested by the estimated pKa value of 6.8, compromised the stability of liposome.  Further 
investigation is needed to balance the pH-sensitivity and stability in vivo.  
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Chapter 7: Summary and Future Work 
 
Breast cancer is a major health care concern and the second leading cause of death 
affecting American women.  Triple negative breast cancer is characterized by lack of expression 
of the estrogen receptor (ER), the progesterone receptor (PR) and the human epidermal growth 
factor receptor (HER2 /neu).  It is the leading fatal subtype of breast cancer with the poorest 
prognosis.  Chemotherapy, individually or in combination with surgery or radiotherapy is 
predominantly given to TNBC patients since TNBC is not responsive to targeted therapies.  
Doxorubicin is one of the most effective drugs used in the treatment of TNBC, but it has serious 
adverse effects, especially cardiotoxicity associated with the accumulation use of free drug.  
Liposomes are one of the widely used drug delivery systems to facilitate physical targeting, in 
which preferred accumulation is achieved by the EPR effect for the treatment of solid tumors. 
Stimuli-response, such as a reverse pH gradient at tumor site, can ramp up the release rate of 
anticancer agent, consequently makes more free drug available to exert its biological effect.  A 
combination of a physical targeting approach with a pH triggered release strategy can have a 
significant impact on overall effectiveness of the therapy against TNBC.  The objective of this 
dissertation work was to develop and evaluate doxorubicin loaded pH-sensitive liposomes for 
drug delivery against TNBC. 
pH-sensitive fliposomes with conformational switch lipids were successfully prepared by 
thin film hydration.  In order to have a standardized procedure, ethanol injection followed by 
tangential flow filtration was developed to prepare fliposomes.  The metal ion remote loading 
method was developed to circumvent the increasing proton concentration caused by the 
traditional ammonium gradient remote loading methods.  Fliposomes carried high encapsulation 
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efficiency (>80%), small mean particle size (<200 nm) and small PDI (<0.3), indicating the 
robustness of the preparation procedure.  
It is critical to have a reliable method to evaluate pH-sensitivity of fliposomes in vitro 
since the release of our delivery system is triggered by the reverse pH gradient at the tumor site.  
Several release assays for DOX-loaded liposomes, including traditional dialysis methods, 
fluorescent methods and our new resin adsorption methods were evaluated.  Adsorption of 
positive charged doxorubicin onto the cellulose membrane of dialysis tubing made dialysis not 
reflect the real release profile while various degradation rates of DOX in different pH buffer 
reversed the intensity of fluorescent measurement.  Taking the complexity of the operation 
procedure into consideration for high throughput evaluation, the direct resin adsorption method 
appears to be the most practical and feasible method to kinetically monitor the release profile of 
pH-sensitive liposomes in vitro.  The pH-sensitivity of fliposomes evaluated by direct resin 
adsorption method was validated with calcein loaded fliposomes, in which calcein is a 
commonly used water-soluble fluorescent probe for investigating drug release from liposomes.  
The pH-sensitive release of doxorubicin from fliposomes was similar with the release of calcein 
in fliposomes. 
In order to maximize the benefit of liposomes for anticancer therapy, the properties of 
fliposomes need to be optimized to achieve effective physical targeting and pH-sensitive release.  
In addition to triggered release, which is a focus for this dissertation, stability, small and 
homogeneous size, and adequate drug-loading capacity are all important properties of liposomes 
for anticancer therapy.  All those physical properties except for size are related to components of 
liposomes other than the preparation procedure.  Therefore, identification of the factors 
impacting the outcome of physical targeting and the optimization of fliposomes were based on 
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the lipid composition in this dissertation.  The neutral pegylated lipid, PEG-Ceramide was 
chosen for enhanced pH-sensitivity.  Cholesterol and long hydrocarbon tail phospholipid, such as 
DSPC were necessary for the stability of the liposomes, while the incorporation of cholesterol 
and DSPC compromised the release in response to the desired pH.  With an increasing mole 
percentage of flipid, the pH-sensitivity of fliposomes was increased, while the homogeneity, and 
consequently in vivo stability was sacrificed, indicated by a drastic increase of size and PDI.  In 
early studies, AZE-C16-based fliposomes showed quick response of release to the desired pH, 
but less stability.  RSM was utilized to further optimize the AZE-C16 based fliposome.  AZE: 
DSPC: Chol: PEG-Ceramide = 38: 32: 25: 5 was predicted by RSM to have relatively high 
stability and pH-sensitivity.  
Before evaluating the efficacy in an in vivo model, we evaluated the anticancer efficacy 
of fliposome in vitro.  3D MCS are self-assembled cultures of tumor cells formed in conditions 
where cell-cell interactions predominate over cell-substrate interactions.  3D MCS include many 
features of solid tumors that are missing in 2D monolayer cells, especially the reverse pH 
gradient.  Therefore, 3D MCS mimic the native and complex tumor microenvironment, thus can 
serve as a valid and clinically relevant in vitro model to evaluate efficacy of fliposomes.  Two 
3D TNBC MCS, MDA-MB-231 and MDA-MB-468, were successfully established for in vitro 
efficacy evaluation.  Cell viability and the pH gradient inside 3D MCS were validated by laser 
confocal microscopy to confirm that MCS possess the essential microenvironment.  Free DOX, 
DOX-loaded conventional liposomes and DOX-loaded fliposomes were evaluated in the 3D 
MCS model for anticancer efficacy.  IC50 value for all treatment groups against 3D MCS was 
much greater than the IC50 value against 2D monolayer cells, which could be explained by the 
fact that penetration resistance was much higher in the 3D MCS model.  DOX-loaded 
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Fliposomes, especially the MOR-C16 fliposome (DPPC : Mor-C16 : PEG-Ceramide = 70 : 25 : 
5), showed improved efficacy than the conventional liposome based on IC50 value.   
A pilot pharmacokinetic study of AZE-C16 fliposome was conducted in female athymic 
nude mice due to concerns of stability with AZE-C16 fliposomes.  The results showed that the 
concentration of DOX in blood dropped quickly lower than 0.3 µg/ml (the IC50 value on 3D 
MCS) within 12 hours.  The pharmacokinetic profile of AZE-C16 fliposomes was similar with 
free doxorubicin, which indicated premature leakage from AZE-C16 fliposomes in circulation.  
A pharmacokinetic study of MOR-C16 fliposomes is also needed to correlate with the in vitro 
stability and pharmacokinetic study with the eventual efficacy results and compare the outcome 
of AZE-C16 and MOR-C16 fliposome.  Increasing the dose or improvement in the analytical 
assay could possibly solve the problem of LOQ, which will give better insight into fliposome in 
vivo.  The antitumor efficacy of pH-sensitive fliposomes was evaluated in an orthotopic MDA-
MB-468 xenograft in a nude mouse model, which was the first time that the DOX-loaded 
liposomal formulation conducted the treatment on TNBC orthotopic model.  DOX-loaded 
Fliposomes, especially the MOR-C16 fliposomes showed improved efficacy compared to 
conventional liposomes at day 61 post-first dose, which was suggested by the delay in tumor 
progression.   
As potential work for comprehensive development of fliposome, the further optimization 
of fliposome by RSM, including MOR-C16 flipsome, is very critical.  The stability within 24 
hours should be ranked as the highest priority compared to pH-sensitivity based on current 
research.  In addition, the percentage of components should cover wider range for better 
prediction.  If needed, the independent variables could be added to three factors (flipid%, 
phospholipid% and cholesterol%), by which more interaction could be investigated.  On the 
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other hand, the biodistribution and comprehensive pharmacokinetic studies are necessary to 
investigate doxorubicin exposure to the TNBC as well as normal tissue.  Doxorubicin exposure 
through the EPR effect can be obtained by comparing the drug concentration in tumor of 
fliposome and one of pegylated liposome, therefore the contribution from pH-triggered release 
can be estimated if there is difference suggested in the efficacy with two treatments.  Regarding 
the efficacy evaluation, dose escalation to achieve better tumor regression is another potential 
study for comprehensive experiment design once the final optimization is done. 
There is another perspective need further investigation, which is the correlation between 
in vitro characteristics and in vivo outcome.  The characterization of fliposomes in vitro, such as 
stability or pH sensitivity, is the most common and convenient method to investigate the 
property of fliposomes.  We also have developed the 3D MCS platform to evaluate the 
anticancer efficacy of fliposomes.  How to link different tools in vitro with the outcome of in 
vivo model is critical, for instance, the identification of which characteristic in vitro has the most 
impact on the exposure in 3D MCS, consequently influencing half-life in vivo.  Once the 
correlation is established, different strategies aiming at various in vivo profile can be achieved by 
manipulation of parameters of fliposomes, such as size and particular components. 
In conclusion,  pH-sensitive fliposomes were successfully prepared by thin film hydration 
and ethanol injection methods with appropriate properties for physical targeting.  Direct Resin 
adsorption method was established to evaluate pH-sensitivity of fliposome in vitro.  3D MCS 
and orthotopic TNBC models were successfully established for efficacy evaluation.  
Doxorubicin-loaded fliposomes, especially the MOR-C16 fliposome showed improved 
anticancer efficacy over non pH-sensitive liposome in vitro and in an orthotopic TNBC 
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